Amedeo Smart

Free Medical Literature Service

 

Amedeo

Inflammatory Bowel Diseases
  Free Subscription

Articles published in
J Crohns Colitis
    March 2026
  1. DEMIRLI ATICI S, Canda AE, Terzi MC
    Anatomy is not activity: rethinking MRI fistula volume in perianal Crohn's disease.
    J Crohns Colitis. 2026 Mar 17:jjag031. doi: 10.1093.
    >> Share

  2. WANG Y, Tian G
    Prior anti-tumor necrosis factor exposure and colectomy risk in acute severe ulcerative colitis: time-to-event and target-trial considerations in MOREUS (GETECCU).
    J Crohns Colitis. 2026;20:jjag020.
    >> Share

  3. SINGH A, Bhardwaj A, Jena A, Midha V, et al
    Patient knowledge and awareness on inflammatory bowel disease as it evolves as a global disease: a scoping review.
    J Crohns Colitis. 2026;20:jjag019.
    >> Share

  4. DIGNASS A, Narula N, Pratap K, Danese S, et al
    IOlBD evidence-based consensus on the use of artificial intelligence for assessment of endoscopic and histologic endpoints in clinical trials of inflammatory bowel disease.
    J Crohns Colitis. 2026;20:jjag007.
    >> Share

  5. MAGRO F, Ministro P, de Sousa HT, Roseira J, et al
    Distinct hepcidin patterns in Crohn's disease and ulcerative colitis: links to iron homeostasis and inflammatory activity.
    J Crohns Colitis. 2026;20:jjag023.
    >> Share

  6. DE GREEF E, Turner D, Kierkus J, Korczowski B, et al
    Ustekinumab therapy for moderately to severely active pediatric Crohn's disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg.
    J Crohns Colitis. 2026;20:jjag011.
    >> Share

  7. CHRISTENSEN HS, Larsen L, Lees CW, Bogsted M, et al
    Real-world evidence on medication patterns in inflammatory bowel disease the first decade after diagnosis.
    J Crohns Colitis. 2026;20:jjag025.
    >> Share

  8. JOHANSEN I, Hagen MC, Lokkeberg ST, Aabrekk TB, et al
    Anxiety and depression in newly diagnosed patients with inflammatory bowel disease (the IBSEN III study) compared with the general population in Norway.
    J Crohns Colitis. 2026;20:jjag021.
    >> Share

    February 2026
  9. ESTEVINHO MM, Shakweh E, Cho W, Rozenberg F, et al
    Tunnel vision: Rethinking local therapy for perianal fistulas in Crohn's disease.
    J Crohns Colitis. 2026 Feb 16:jjag008. doi: 10.1093.
    >> Share

  10. CENTANNI L, Fanizzi F, D'amico F, Danese S, et al
    Cutaneous autoimmune blistering disease during mirikizumab therapy in a patient with ulcerative colitis: a new potential trigger?
    J Crohns Colitis. 2026 Feb 13:jjaf235. doi: 10.1093.
    >> Share


  11. Correction to: Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis.
    J Crohns Colitis. 2026;20:jjag002.
    >> Share

  12. HODGES P, Roberts C, Parkes M, Kennedy NA, et al
    Clinical utility of pre-treatment four-digit-resolution HLA genotyping to guide anti-tumor necrosis factor choice and concomitant immunomodulator use.
    J Crohns Colitis. 2026;20:jjaf233.
    >> Share

  13. SAGAMI S, Matsuoka K, Kobayashi T
    Beyond the mucosa: intestinal ultrasound for post-endoscopic healing risk stratification in ulcerative colitis.
    J Crohns Colitis. 2026;20:jjaf224.
    >> Share

  14. MARK-CHRISTENSEN A, Ebert AC, Poulsen GJ, Laurberg S, et al
    Risk of adverse pregnancy and birth outcomes after open versus laparoscopic surgery for inflammatory bowel disease: a nationwide cohort study.
    J Crohns Colitis. 2026;20:jjaf234.
    >> Share

  15. GIUSTO EA, Pinton P, Giorgi C, Serino G, et al
    Risk of intestinal cancer in Crohn's disease: re-analysis and meta-regression of population-based cohort studies.
    J Crohns Colitis. 2026;20:jjag013.
    >> Share

  16. MATELLAN C, Raphael B, Jones GR, Nwaeziegwe M, et al
    TWEAK is increased in ulcerative colitis and contributes to fibroblast-mediated monocyte activation via heterologous non-canonical NF-kB/STAT3 signaling.
    J Crohns Colitis. 2026;20:jjag012.
    >> Share

  17. CHKOLNAIA Z, Peyrin-Biroulet L, Uzzan M
    A descriptive comparison of phase 3 results and head-to-head trials in inflammatory bowel diseases.
    J Crohns Colitis. 2026;20:jjag009.
    >> Share

  18. WILLIAMS S, Meran L, McCartney S, Harrow P, et al
    REACH: C-cause.
    J Crohns Colitis. 2026;20.
    >> Share

  19. SAID H, Moulton CD, Hart A, Keefer L, et al
    Holistic care in inflammatory bowel disease: is it in REACH?
    J Crohns Colitis. 2026;20.
    >> Share

  20. NARDONE OM, Gros B, Parigi TL, Farooq A, et al
    Attaining sustainability in inflammatory bowel disease.
    J Crohns Colitis. 2026;20.
    >> Share

  21. THAKOR A, Yogakanthi S, Noor NM, Parkes M, et al
    Rapid diagnosis and treatment of inflammatory bowel diseases.
    J Crohns Colitis. 2026;20.
    >> Share

  22. BURISCH J, Banerjee R, Watermeyer G
    Equitable access to inflammatory bowel disease care: challenges, strategies, and future directions.
    J Crohns Colitis. 2026;20.
    >> Share

    January 2026
  23. HAWTHORNE AB, Christiansen P, Arnott I, Cummings F, et al
    Comparative analysis of inflammatory bowel disease patient and service reported quality of care using 2019 and 2023 UK benchmarking data from more than 26,000 adult patient respondents and 154 IBD services.
    J Crohns Colitis. 2026 Jan 23:jjag005. doi: 10.1093.
    >> Share

  24. QURAISHI MN, Moakes CA, Yalchin M, Blackwell C, et al
    Mechanistic insights into FMT for the treatment of ulcerative colitis: analysis of the STOP-Colitis trial.
    J Crohns Colitis. 2026 Jan 23:jjag006. doi: 10.1093.
    >> Share

  25. MAGRO F, Rogler G, Feagan BG, Peyrin-Biroulet L, et al
    Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib.
    J Crohns Colitis. 2026 Jan 22:jjaf228. doi: 10.1093.
    >> Share

  26. CHENG S, Cheng C, Huang C, Liu C, et al
    Intermittent ketogenic diet promotes Treg differentiation and alleviates Crohn's disease via the beta-hydroxybutyrate driven AHCY-DNMT1-Foxp3 axis.
    J Crohns Colitis. 2026 Jan 12:jjag003. doi: 10.1093.
    >> Share

  27. JONES F, Lavelle A, McCarthy F, Patchett S, et al
    Quality metrics reflecting patient experience of GI endoscopy in Inflammatory Bowel Disease: results of national endoscopy dataset analysis.
    J Crohns Colitis. 2026 Jan 9:jjaf211. doi: 10.1093.
    >> Share

  28. ORLEMANN T, Zimmermann D, Hubner H, Atreya R, et al
    Intestinal barrier healing is superior to transmural healing to prevent disease progression in clinical remittent patients with inflammatory bowel disease.
    J Crohns Colitis. 2026;20:jjaf232.
    >> Share

    December 2025
  29. PETITO V, Gerovska D, Piazzesi A, di Vincenzo F, et al
    Inflammatory Bowel Disease is associated with increased intestinal extrachromosomal circular DNA: an emerging biomarker for IBD type and activity.
    J Crohns Colitis. 2025 Dec 29:jjaf237. doi: 10.1093.
    >> Share

  30. CHEN C, Guo Y
    Revisiting Patient Stratification and Inflammatory Assessment in Ulcerative Colitis-Associated Colorectal Cancer.
    J Crohns Colitis. 2025 Dec 27:jjaf238. doi: 10.1093.
    >> Share

  31. PRIVITERA G, Bezzio C, Buono AD, Gabbiadini R, et al
    Treat-to-target optimization of biologic therapy is effective on endoscopic and histologic outcomes in a real-life cohort of ulcerative colitis-the TACTIC-UC study.
    J Crohns Colitis. 2025 Dec 27:jjaf239. doi: 10.1093.
    >> Share

  32. AXI L, Wang Y, Meng W
    Research Progress on Exclusive Enteral Nutrition Combined with Biologics in the Treatment of Adult Crohn's Disease.
    J Crohns Colitis. 2025 Dec 26:jjaf236. doi: 10.1093.
    >> Share

  33. RUEDA GARCIA JL, Lowenberg M
    Towards tailored surveillance strategies in inflammatory bowel disease: still a long way to go.
    J Crohns Colitis. 2025;19:jjaf217.
    >> Share


  34. Correction to: Restoring Prostacyclin/PGI2-PTGIR signaling alleviates intestinal fibrosis in Crohn's disease via fibroblast-specific YAP/TAZ inhibition.
    J Crohns Colitis. 2025;19:jjaf142.
    >> Share

  35. DOLOVICH C, Chochinov S, Ly G, Oketola B, et al
    The complex relationship between physical activity and fatigue with socioeconomic status, and mental health factors in individuals with inflammatory bowel disease.
    J Crohns Colitis. 2025;19:jjaf212.
    >> Share

  36. SIRANART N, Nakaphan P, Pajareya P, Laohasurayotin K, et al
    Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis.
    J Crohns Colitis. 2025;19:jjaf193.
    >> Share

  37. KUNISAKI R, Kimura H, Maeda S
    Guselkumab-mediated marked improvement in a case of refractory ulcerative colitis resistant to mirikizumab: evidence for switching between IL-23p19 inhibitors.
    J Crohns Colitis. 2025 Dec 15:jjaf230. doi: 10.1093.
    >> Share

  38. AXELRAD J, Forss A, Soderling J, Marild K, et al
    Risk of serious infections in patients with inflammatory bowel disease treated with biologic and small molecule therapies: A nationwide cohort study.
    J Crohns Colitis. 2025 Dec 15:jjaf229. doi: 10.1093.
    >> Share

  39. WASHBURN S, Hwang Y, Chowdary Maddipatla S, Murthy S, et al
    Identification of Crohn's disease subtypes in single cell RNA sequencing signatures of treatment naive samples across the paediatric gastrointestinal tract.
    J Crohns Colitis. 2025 Dec 10:jjaf225. doi: 10.1093.
    >> Share

  40. ZHANG Q, Sharip M, Roberts C, Shakweh E, et al
    HLA-DQA1*05:01 and DQA1*05:05 inform choice of anti-tumor necrosis factor and concomitant use of immunomodulators in patients with inflammatory bowel disease.
    J Crohns Colitis. 2025;19:jjaf195.
    >> Share

  41. DE CRISTOFARO E, Marafini I, Franchin M, Venuto C, et al
    Frequency of dysplasia in endoscopically resected pseudopolyps in inflammatory bowel diseases.
    J Crohns Colitis. 2025;19:jjaf196.
    >> Share

  42. NEWMAN KL, Naftaly JP, Wren PA, Long MD, et al
    Direct and indirect impacts of discrimination, internalized stigma, and disease disclosure on inflammatory bowel disease patient health outcomes.
    J Crohns Colitis. 2025;19:jjaf192.
    >> Share

  43. PEYRIN-BIROULET L, Atreya R, Danese S, Lindsay JO, et al
    Efficacy and Safety of Risankizumab in Patients with Moderately to Severely Active Crohn's Disease: Interim Results from the SEQUENCE Open-Label Extension Study.
    J Crohns Colitis. 2025 Dec 4:jjaf213. doi: 10.1093.
    >> Share

  44. PAPAGEORGIOU N, Haidich AB, Pagkalidou E, Papaemmanouil A, et al
    The global leadership initiative on malnutrition criteria for the diagnosis of malnutrition in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2025 Dec 3:jjaf209. doi: 10.1093.
    >> Share

  45. IKEBATA A, Okabayashi K, Uchino M, Ikeuchi H, et al
    Background Mucosal Inflammation Affects Colorectal Cancer Prognosis in Ulcerative Colitis: A Nationwide, Multicenter Study.
    J Crohns Colitis. 2025 Dec 3:jjaf207. doi: 10.1093.
    >> Share

  46. FERNANDES RG, Khoo E, Jensen Harris H, Gilmore R, et al
    Cost-effective inflammatory bowel disease flare pathway with nurse-led triage and rapid access intestinal ultrasound reduces hospital resource use with high patient satisfaction.
    J Crohns Colitis. 2025 Dec 2:jjaf221. doi: 10.1093.
    >> Share

  47. SUL HH, Gewehr DM, Kang H, Junior OR, et al
    Efficacy of 5-Aminosalicylic Acid Continuation versus Discontinuation in Patients with Ulcerative Colitis Escalated to Advanced Therapy: A Systematic Review and Meta-Analysis of Adjusted Effect Estimates.
    J Crohns Colitis. 2025 Dec 2:jjaf202. doi: 10.1093.
    >> Share

    November 2025
  48. ANAND E MR, Anandabaskaran S Dr, Pelly T Mr, Hart A Professor, et al
    Real-world evaluation of MRI fistula volume as a radiological biomarker of disease activity in perianal fistulising crohn's disease.
    J Crohns Colitis. 2025 Nov 29:jjaf216. doi: 10.1093.
    >> Share

  49. WEWER MD, Burisch J, Myrelid P, Olen O, et al
    Apples and Oranges? Comparison of Early Ileocolic Resection and Medical Treatment for Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2025 Nov 29:jjaf218. doi: 10.1093.
    >> Share

  50. ANDERSEN JW, Troelsen FS, Haldrup D, Krogh K, et al
    Cumulative Incidence and Risk Factors for Advanced Neoplasia following Inflammatory Bowel Disease-Related Low-Grade Dysplasia: A Danish Nationwide Cohort Study.
    J Crohns Colitis. 2025 Nov 29:jjaf219. doi: 10.1093.
    >> Share

  51. HONAP S, Debouverie M, Filippi M, Selchen D, et al
    Inflammatory Bowel Disease therapies and Demyelinating Diseases: A Practical Guide to Therapeutic Benefit and Risk.
    J Crohns Colitis. 2025 Nov 29:jjaf215. doi: 10.1093.
    >> Share

  52. WANG Y, Wang H, Wu X, Duan X, et al
    Development and validation of a novel multimodal deep learning model integrating histopathology, radiology, and clinical data to predict primary non-response to infliximab in patients with crohn's disease.
    J Crohns Colitis. 2025 Nov 26:jjaf206. doi: 10.1093.
    >> Share

  53. LIM CT, Teichert C, Gecse K
    Beyond the Mucosa: Intestinal Ultrasound for Post Endoscopic Healing Risk Stratification in Ulcerative Colitis-Authors' Reply.
    J Crohns Colitis. 2025 Nov 25:jjaf199. doi: 10.1093.
    >> Share

  54. KATSOULA A, Paschos P, Malandris K, Kalogirou MS, et al
    Systematic Review and Network Meta-Analysis: Evaluating the Impact of advanced therapies for Moderate-to-Severe Ulcerative Colitis on Health-Related Quality of Life.
    J Crohns Colitis. 2025 Nov 24:jjaf210. doi: 10.1093.
    >> Share

  55. MIGLIORISI G, Delaplace R, Honap S, Germain A, et al
    From Resection to Preservation: Redefining the Surgical Paradigm in Crohn's Disease.
    J Crohns Colitis. 2025 Nov 24:jjaf208. doi: 10.1093.
    >> Share

  56. VERMEIRE S, Colombel JF, Danese S, Panaccione R, et al
    Benefit-Risk Profile of Upadacitinib: Exploratory Post Hoc Analysis of Phase 2b/3 Studies in Patients With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2025 Nov 20:jjaf198. doi: 10.1093.
    >> Share

  57. IACUCCI M, Majumder S, Zammarchi I, Santacroce G, et al
    Automated real-time imaging of intestinal barrier integrity and molecular profiling for early outcome prediction in inflammatory bowel disease - Endo-Histo-Barrier-Omics study.
    J Crohns Colitis. 2025 Nov 19:jjaf200. doi: 10.1093.
    >> Share

  58. MOOJEN TB, Vlug MS, Visser E, Reijntjes MA, et al
    Modified-2-stage versus 3-stage approach in ileoanal pouch surgery for Ulcerative Colitis.
    J Crohns Colitis. 2025 Nov 19:jjaf201. doi: 10.1093.
    >> Share

  59. VENKAT S, Zeeman M, Hart A, Bhagat S, et al
    Serum Protein Profiles Differ with Adalimumab and Ustekinumab Treatment in Moderately to Severely Active Crohn's Disease.
    J Crohns Colitis. 2025 Nov 19:jjaf197. doi: 10.1093.
    >> Share

  60. LLAO J, Manosa M, Martin-Arranz E, Zabana Y, et al
    Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: A randomized, multicentre, open-label study by GETECCU.
    J Crohns Colitis. 2025 Nov 19:jjaf182. doi: 10.1093.
    >> Share

  61. WONG ECL, Marshall JK, Ma C, Jairath V, et al
    Addition of Baseline Histology and Fecal Calprotectin Does Not Reduce Placebo Rates in Ulcerative Colitis Clinical Trials: Post-hoc Analysis of Patient Level Data.
    J Crohns Colitis. 2025 Nov 9:jjaf194. doi: 10.1093.
    >> Share

  62. SOLITANO V, Hogan M, Singh S, Danese S, et al
    Placebo rates in randomised clinical trials of ulcerative colitis: An individual patient data meta-analysis.
    J Crohns Colitis. 2025 Nov 9:jjaf191. doi: 10.1093.
    >> Share

  63. HYON SS, Elsawwah JK, Shaikh FA, Flanagan JS, et al
    Comparison of Early Ileocolic Resection and Medical Treatment for Crohn's Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2025 Nov 9:jjaf190. doi: 10.1093.
    >> Share

  64. MOREIRA PL, Dignass A, Estevinho MM, Santiago M, et al
    Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-survey.
    J Crohns Colitis. 2025;19:jjaf178.
    >> Share

  65. SINGH S, Desai A, Goodwin S, Jairath V, et al
    Trends in utilization of advanced therapies in patients with inflammatory bowel diseases in the USA, 2021-2025.
    J Crohns Colitis. 2025;19:jjaf186.
    >> Share

  66. BOUWKNEGT DG, Hoekstra B, Donker HC, van Es B, et al
    How long is long enough? Timing of pre-conceptional remission predicts relapse risk during pregnancy in IBD.
    J Crohns Colitis. 2025;19:jjaf176.
    >> Share

  67. FRIGERIO S, Khan HN, Amini M, Mol B, et al
    Spatial transcriptomics and immunophenotyping uncover chronic inflammation-induced immune adaptations favoring dysplasia development in patients at risk of colitis-associated cancer.
    J Crohns Colitis. 2025;19:jjaf184.
    >> Share

  68. INNOCENTI T, Hanzel J, Truyens M, Lukas M, et al
    Sequencing JAK-inhibitors in ulcerative colitis: effectiveness and safety of switching within treatment class.
    J Crohns Colitis. 2025 Nov 3:jjaf188. doi: 10.1093.
    >> Share

    October 2025
  69. CHATTO M, Alaskar D, Ma C, Yuan Y, et al
    Pharmacological management of upper gastrointestinal crohn's disease: A systematic review.
    J Crohns Colitis. 2025 Oct 28:jjaf187. doi: 10.1093.
    >> Share

  70. PRUIJT MJ, Teichert C, De Voogd FA, Janssen RJ, et al
    Kinetics of Intestinal Ultrasound and Shear-wave Elastography to assess early response in Ulcerative Colitis Patients Treated with Filgotinib.
    J Crohns Colitis. 2025 Oct 28:jjaf185. doi: 10.1093.
    >> Share

  71. FRANCISCO M, Alicia LG, Jose MB, Cristina RC, et al
    Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-TNF drugs: a comparative study of GETECCU.
    J Crohns Colitis. 2025 Oct 25:jjaf183. doi: 10.1093.
    >> Share

  72. BATTAT R, Sangiorgi B, Linggi B, Gui X, et al
    Spatial transcriptomics reveals unique inflammatory signatures across all anatomic locations in post-operative crohn's disease.
    J Crohns Colitis. 2025 Oct 15:jjaf180. doi: 10.1093.
    >> Share

  73. MACALUSO FS, Fries W, Viola A, Cappello M, et al
    Switching to subcutaneous administration may offer more profound remission compared to intensified intravenous therapy in patients with inflammatory bowel disease and partial response following induction with intravenous vedolizumab: the PRIVEDO study
    J Crohns Colitis. 2025 Oct 13:jjaf175. doi: 10.1093.
    >> Share

  74. BAYOUMY AB, Clarke LM, Deepak P, Desai A, et al
    Glucagon-Like Peptide 1 Receptor Agonists (GLP1-RA) and the Clinical Outcomes of Inflammatory Bowel Disease (IBD): A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2025 Oct 10:jjaf181. doi: 10.1093.
    >> Share

  75. IBING S, Tastad C, Renard BY, Cohen LJ, et al
    Disease duration impacts intestinal gene expression profiles in crohn's disease but not in ulcerative colitis.
    J Crohns Colitis. 2025 Oct 8:jjaf179. doi: 10.1093.
    >> Share

  76. BALDAN-MARTIN M, Iloro I, Azkargorta M, Soleto I, et al
    Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.
    J Crohns Colitis. 2025 Oct 8:jjaf177. doi: 10.1093.
    >> Share

    September 2025

  77. Correction to: Novel outcomes in inflammatory bowel disease.
    J Crohns Colitis. 2025;19:jjaf117.
    >> Share

  78. NIKOLAKIS D, Li Yim AYF, Overberg KL, Ghiboub M, et al
    Drug repurposing approach for the discovery of therapeutic agents for Crohn's disease-associated intestinal fibrosis.
    J Crohns Colitis. 2025;19:jjaf137.
    >> Share


  79. Correction to: Spatial immune profiling of Crohn's disease fistula carcinomas-defining a distinct cancer subtype.
    J Crohns Colitis. 2025;19:jjaf171.
    >> Share

  80. VEYSSIERE M, Hammoudi N, Le Bourhis L, Hassid D, et al
    Blood proteomic signatures associated with disease activity in inflammatory bowel diseases.
    J Crohns Colitis. 2025;19:jjaf162.
    >> Share

  81. SAMAAN MA, Cunningham G, Lim SH, Dawson P, et al
    Fecal loss of vedolizumab is associated with ulcerative colitis severity, lower serum vedolizumab levels, and rates of clinical response: results from the FAVOUR study.
    J Crohns Colitis. 2025;19:jjaf159.
    >> Share

  82. CHKOLNAIA Z, Reinisch W, Uzzan M
    Modulating checkpoint molecules in inflammatory bowel diseases as a new therapeutic strategy: a narrative review.
    J Crohns Colitis. 2025;19:jjaf160.
    >> Share

  83. NI L, Peng X, Huang Y, Zhu Y, et al
    Assessing intestinal fibrosis using an endoscopic photoacoustic-ultrasound balloon catheter in rabbits and a human subject.
    J Crohns Colitis. 2025;19:jjaf155.
    >> Share

  84. RADIA C, Danso Y, Ritchie S, Hale M, et al
    Is 2nd JAKi treatment for UC worth the effort? A retrospective, multi-centre UK study.
    J Crohns Colitis. 2025;19:jjaf154.
    >> Share

  85. NOOR NM, Davies N, Tahir W, Bond S, et al
    Anti-tumor necrosis factor treatment from diagnosis is more effective and less costly than conventional "step-up" care for patients with active Crohn's disease: a cost-effectiveness analysis from the PROFILE trial.
    J Crohns Colitis. 2025;19:jjaf150.
    >> Share

  86. BRAND EC, Roosenboom B, Lutter L, Malvar Fernandez B, et al
    Mucosal Kinase Activity and Inflammatory Profiles in Inflammatory Bowel Disease, and in Relation with Tofacitinib Response.
    J Crohns Colitis. 2025 Sep 23:jjaf174. doi: 10.1093.
    >> Share

  87. HILLEY P, Chin S, Wong D, De Cruz P, et al
    Implementation of Values based healthcare in inflammatory bowel disease-a review article.
    J Crohns Colitis. 2025 Sep 19:jjaf173. doi: 10.1093.
    >> Share

  88. ROTEM-TRYFUS O, Kang B, Orlanski-Meyer E, Ledder O, et al
    Validation of prediction models for anti-tumor necrosis factor treatment response in pediatric Crohn's disease: a systematic review and prospective cohort study.
    J Crohns Colitis. 2025 Sep 19:jjaf172. doi: 10.1093.
    >> Share

  89. LEGA S, Dipasquale V, D'arcangelo G, Scarallo L, et al
    Real-Life Durability and Risk Factors for Biologic Discontinuation in Pediatric Inflammatory Bowel Disease: Results from the Sigenp IBD Registry.
    J Crohns Colitis. 2025 Sep 19:jjaf164. doi: 10.1093.
    >> Share

  90. RAJA SS, Costello SP, Rayner CK, Day A, et al
    Examining the role of faecal microbiota transplantation for inducing remission in resistant ulcerative proctitis and distal ulcerative colitis (up-FMT).
    J Crohns Colitis. 2025 Sep 18:jjaf169. doi: 10.1093.
    >> Share

  91. ALLOCCA M, Jairath V, Sands BE, Rubin DT, et al
    International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials.
    J Crohns Colitis. 2025 Sep 18:jjaf170. doi: 10.1093.
    >> Share

  92. COLWILL M, Povlsen S, Pollok R, Patel K, et al
    Glucagon-Like Peptide (GLP-1) Receptor Agonists in Inflammatory Bowel Disease: Mechanisms, Clinical Implications, and Therapeutic Potential.
    J Crohns Colitis. 2025 Sep 16:jjaf167. doi: 10.1093.
    >> Share

  93. WILS P, Altwegg R, Buisson A, Vuitton L, et al
    Subcutaneous vedolizumab dose intensification in inflammatory bowel disease patients: the OPTI-VEDO multicenter study from the GETAID.
    J Crohns Colitis. 2025 Sep 10:jjaf166. doi: 10.1093.
    >> Share

  94. MAHADEVAN U, Seow CH, Barnes EL, Chaparro M, et al
    Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025;19:jjaf129.
    >> Share

  95. MASSIMINO L, Solitano V, Ungaro F
    Repurposing losartan for fibrostenosing Crohn's disease: a compelling preclinical rationale.
    J Crohns Colitis. 2025;19:jjaf147.
    >> Share

  96. FAGGIANI I, Bencardino S, Peyrin-Biroulet L
    Catching fibrosis in motion: time-dependent diffusion MRI-derived cell diameter reveals the transitional state of intestinal scarring in Crohn's disease.
    J Crohns Colitis. 2025;19:jjaf146.
    >> Share


  97. Correction to: Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study.
    J Crohns Colitis. 2025;19:jjaf123.
    >> Share

  98. WANG Z, Ferrante M, Vermeire S, Dreesen E, et al
    Optimizing the switch from escalated intravenous to subcutaneous infliximab: a population pharmacokinetics-pharmacodynamics study.
    J Crohns Colitis. 2025;19:jjaf151.
    >> Share

  99. JANS DS, Depovere J, Lee HS, Abakkouy Y, et al
    Unravelling the genetic architecture of inflammatory bowel disease multiplex families with rare and common variant polygenic risk scores.
    J Crohns Colitis. 2025 Sep 5:jjaf165. doi: 10.1093.
    >> Share

  100. NERI B, Schiavone SC, Mancone R, Fiorillo M, et al
    Clinical Outcome After Entero-Enteric Anastomosis for Crohn's Disease: A Case-Control Study.
    J Crohns Colitis. 2025 Sep 5:jjaf163. doi: 10.1093.
    >> Share

  101. GISBERT JP, Chaparro M
    Combination therapy with biologics and/or small molecules in inflammatory bowel disease: a comprehensive review.
    J Crohns Colitis. 2025 Sep 3:jjaf161. doi: 10.1093.
    >> Share

  102. PRUIJT MJ, Neefjes-Borst EA, De Voogd FAE, Lange MM, et al
    Submucosal hyper-echogenicity on intestinal ultrasound is associated with fat deposition and predicts treatment non-response in patients with ulcerative colitis.
    J Crohns Colitis. 2025 Sep 1:jjaf158. doi: 10.1093.
    >> Share

    August 2025
  103. LIM CT, Teichert C, Pruijt M, De Voogd F, et al
    Transmural healing in ulcerative colitis patients improves long-term outcomes compared to endoscopic healing alone.
    J Crohns Colitis. 2025 Aug 22:jjaf149. doi: 10.1093.
    >> Share

  104. MASSIRONI S, Solitano V, Furfaro F, D'Amico F, et al
    Impact of Type 2 Diabetes on Clinical Outcomes and Advanced Therapy Use in Patients with Crohn's Disease: a Real-World Propensity Score-Matched Analysis.
    J Crohns Colitis. 2025 Aug 21:jjaf157. doi: 10.1093.
    >> Share

  105. HAANAPPEL AEG, Moojen TB, Vlug MS, Hompes R, et al
    Impact of advanced therapies on surgical recurrence following second ileocolic resection in Crohn's disease.
    J Crohns Colitis. 2025 Aug 21:jjaf156. doi: 10.1093.
    >> Share

  106. BAK MTJ, Boland K, Nayeri S, Borowksi K, et al
    Micronutrients are associated with endoscopic postoperative recurrence in Crohn's disease: a multicenter prospective cohort study in North america.
    J Crohns Colitis. 2025 Aug 20:jjaf148. doi: 10.1093.
    >> Share

  107. MAGRO F, Domingues B, Estevinho MM, Patita M, et al
    Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on Infliximab.
    J Crohns Colitis. 2025 Aug 11:jjaf120. doi: 10.1093.
    >> Share

  108. CALVET X, Ferrario MG, Marfil V, Armenteros S, et al
    Patient-Reported Outcome Measures Poorly Correlate with Objective Inflammatory Bowel Disease Activity Measures: A Systematic Review.
    J Crohns Colitis. 2025 Aug 8:jjaf132. doi: 10.1093.
    >> Share

  109. HAMAM H, Dulai PS, Marshall JK, Ma C, et al
    Impact of Concomitant Corticosteroid Use on Adverse Events in Ulcerative Colitis Clinical Trials.
    J Crohns Colitis. 2025 Aug 5:jjaf145. doi: 10.1093.
    >> Share

  110. SAGAMI S, Odajima K, Asonoma K, Miyatani Y, et al
    Early Reduction in Rectal Wall Thickness on Transperineal Ultrasound Predicts Mucosal Healing in Ulcerative Colitis.
    J Crohns Colitis. 2025 Aug 5:jjaf141. doi: 10.1093.
    >> Share

  111. LEV-TZION R, Dolev AS, Yuval Bar-Asher S, Balicer R, et al
    Machine learning for predicting crohn's disease from routine blood tests years before diagnosis: results from the epi-IIRN cohort.
    J Crohns Colitis. 2025 Aug 4:jjaf143. doi: 10.1093.
    >> Share

  112. PUGLIANO CL, Liang RF, Ruffa A, Iacucci M, et al
    Practical Considerations for the use of IL-23p19 Inhibitors in Inflammatory Bowel Disease: How to Choose Between Them and Why it Matters?
    J Crohns Colitis. 2025 Aug 1:jjaf144. doi: 10.1093.
    >> Share

    July 2025
  113. LOFTUS EV JR, D'Haens G, Louis E, Regueiro M, et al
    Efficacy and Safety of Upadacitinib Maintenance Therapy in Patients with Moderately to Severely Active Crohn's Disease: 2-Year Results from the U-ENDURE Long-Term Extension Study.
    J Crohns Colitis. 2025 Jul 24:jjaf138. doi: 10.1093.
    >> Share

  114. MASSIMINO L, Parigi TL, Riva M, Nicolo S, et al
    Spatiotemporal analysis of Crohn's disease reveals PECAM2 signaling at the basis of inflammation-to-fibrosis transition.
    J Crohns Colitis. 2025 Jul 18:jjaf130. doi: 10.1093.
    >> Share

  115. VUYYURU SK, Alphonsus L, De Silva TA, Solitano V, et al
    Day 3 Oxford Criteria Predict Steroid non-response for Acute Severe Ulcerative Colitis in the Post Biologic Era.
    J Crohns Colitis. 2025 Jul 18:jjaf131. doi: 10.1093.
    >> Share

  116. KHAN S, Dahiya DS, Jadoon AK, Khan DA, et al
    A Network Meta-analysis of Capsule Endoscopy Versus Imaging Modalities for Diagnosing Small Bowel Crohn's Disease.
    J Crohns Colitis. 2025 Jul 15:jjaf127. doi: 10.1093.
    >> Share

  117. MERINGER H, Kayal M, Jairath V, Qasim A, et al
    Scoring indices for assessing endoscopic disease activity in acute severe ulcerative colitis: A systematic review.
    J Crohns Colitis. 2025 Jul 12:jjaf126. doi: 10.1093.
    >> Share

  118. WANG Y, Xue H, Olen O, Everhov AH, et al
    Clonal hematopoiesis of indeterminate potential and risk of incident Crohn's disease-a prospective cohort study.
    J Crohns Colitis. 2025 Jul 12:jjaf118. doi: 10.1093.
    >> Share

  119. COLOMBEL JF, Wu J, Kobayashi T, Zhu B, et al
    Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint.
    J Crohns Colitis. 2025 Jul 12:jjaf124. doi: 10.1093.
    >> Share

  120. EL-HUSSUNA A, Hauer AC, Karakan T, Pittet V, et al
    ECCO consensus on management of Inflammatory Bowel Disease in low-and middle-income countries.
    J Crohns Colitis. 2025 Jul 12:jjaf125. doi: 10.1093.
    >> Share

  121. SVOLOS V, Gordon H, Lomer MCE, Aloi M, et al
    ECCO Consensus on Dietary Management of Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Jul 12:jjaf122. doi: 10.1093.
    >> Share

  122. WANG X, Huang L, Lin S, Shen X, et al
    MR Cell Size Imaging Revealing Intestinal Fibrosis to Predict Intestinal Disease Progression in Patients with Crohn's Disease.
    J Crohns Colitis. 2025 Jul 8:jjaf119. doi: 10.1093.
    >> Share

  123. WANG Y, Huang Y, Hashash JA, Odah T, et al
    Recombinant Herpes Zoster Vaccine Lowers Shingles Complication Risk in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Jul 7:jjaf116. doi: 10.1093.
    >> Share

  124. VERSTOCKT S
    Creeping fat in Crohn's disease: an immunometabolic imbalance worth targeting?
    J Crohns Colitis. 2025;19:jjaf109.
    >> Share

  125. FIORINO G, Walsh A, Adamina M, Barreiro-de Acosta M, et al
    Gaps between European Crohn's Colitis Organisation quality standards of care and the real world on structure of IBD units across Europe: results from E-QUALITY survey.
    J Crohns Colitis. 2025;19:jjaf094.
    >> Share

  126. LIU LJ, Muller TM, Dedden M, Schramm S, et al
    ST6GAL1 promotes IBD B cell recruitment to the inflamed colon in a CD22-dependent mechanism.
    J Crohns Colitis. 2025;19:jjaf097.
    >> Share

  127. WU F, Xie W, Yu A, Lin X, et al
    Lysophosphatidylcholine-induced aberrant adipogenesis in mesenchymal stem cells and impaired antibacterial function in adipocytes of creeping fat.
    J Crohns Colitis. 2025;19:jjaf019.
    >> Share

  128. SOLITANO V, Peyrin-Biroulet L, Danese S
    Long-term efficacy of JAK inhibitors in ulcerative colitis: tipping toward safe success.
    J Crohns Colitis. 2025;19:jjaf114.
    >> Share

  129. ALLOCCA M, Calabrese E
    Ultrasound-guided strategies in ulcerative colitis: early prediction and targeting.
    J Crohns Colitis. 2025;19:jjaf113.
    >> Share

  130. KOVILEIN J, Sorbie A, Khaloian S, Kuntzel V, et al
    Susceptibility to inflammatory bowel diseases promotes invasive carcinomas in a murine model of ATF6-driven colon cancer.
    J Crohns Colitis. 2025;19:jjaf102.
    >> Share

  131. VIEUJEAN S, Sands BE, Panaccione R, Rubin DT, et al
    Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.
    J Crohns Colitis. 2025;19:jjaf111.
    >> Share

  132. PESESKY M, Bharanikumar R, Le Bourhis L, ElAbd H, et al
    Antigen-driven expansion of public clonal T-cell populations in inflammatory bowel diseases.
    J Crohns Colitis. 2025;19:jjaf048.
    >> Share

  133. KUCHARZIK T, Taylor S, Allocca M, Burisch J, et al
    ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 1.
    J Crohns Colitis. 2025;19:jjaf106.
    >> Share

  134. BAO MM, Kars ME, Zhang D, Gettler K, et al
    Phenome-wide association study of monogenic inflammatory bowel disease genes in diverse biobanks identifies population-specific and shared Goldilocks alleles: implications for Precision Medicine.
    J Crohns Colitis. 2025;19:jjaf098.
    >> Share

  135. YANAI H, Feakins R, Allocca M, Burisch J, et al
    ECCO-ESGAR-ESP-IBUS Guideline on Diagnostics and Monitoring of Patients with Inflammatory Bowel Disease: Part 2.
    J Crohns Colitis. 2025;19:jjaf107.
    >> Share

  136. ROBLIN X, Vieujean S, Nancey S, Hebuterne X, et al
    Comparing standard versus intensified pneumococcal vaccination regimens in patients with inflammatory bowel disease on biologics: a prospective, multicenter, randomized, open-label study.
    J Crohns Colitis. 2025;19:jjaf115.
    >> Share

    June 2025
  137. IACUCCI M, Santacroce G, Meseguer P, Dieguez A, et al
    Endo-Histo Foundational Fusion Model: A Novel Artificial Intelligence For Assessing Histologic Remission And Response To Therapy In Ulcerative Colitis Clinical Trial.
    J Crohns Colitis. 2025 Jun 23:jjaf108. doi: 10.1093.
    >> Share

  138. YZET C, Brazier F, Derval E, Vanelslander P, et al
    Impact of complete vs partial endoscopic healing on long-term outcomes in Crohn's disease: a prospective multicenter study.
    J Crohns Colitis. 2025 Jun 18:jjaf104. doi: 10.1093.
    >> Share

  139. FIORINO G, Fidalgo C, Adamina M, Barreiro-de Acosta M, et al
    Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
    J Crohns Colitis. 2025 Jun 17:jjaf105. doi: 10.1093.
    >> Share

  140. CARBONNEL F, Barnich N, Lepage P, Hebuterne X, et al
    A Randomized Controlled Trial Of Antibiotics Targeting Adherent And Invasive Escherichia Coli (Aiec) Vs Placebo In Crohn's Disease: The Teorem Trial.
    J Crohns Colitis. 2025 Jun 13:jjaf093. doi: 10.1093.
    >> Share

  141. REGUEIRO M, Fischer M, Bossuyt P, Protic M, et al
    Impact of Mirikizumab Treatment on Fatigue in Patients with Moderately to Severely Active Crohn's Disease: Results from the Phase 3 VIVID-1 Study.
    J Crohns Colitis. 2025 Jun 10:jjaf100. doi: 10.1093.
    >> Share

  142. KIM KA, Kwon J, Shon WJ, Kim JS, et al
    Association between Food Diversity in the Infant Period and the Risk of Inflammatory Bowel Disease: A Nationwide Cohort Study in South Korea.
    J Crohns Colitis. 2025 Jun 10:jjaf101. doi: 10.1093.
    >> Share

  143. SHANI U, State M, Mateescu RB, Davidoiu AM, et al
    The Effectiveness of second-and-third line biologics in perianal Crohn's disease - a multicenter propensity score-matched study.
    J Crohns Colitis. 2025 Jun 10:jjaf099. doi: 10.1093.
    >> Share

  144. LINGGI B, Filice M, Sangiorgi B, Smith MI, et al
    Metabolism and Response to Stress Gene Signatures Reveal Ulcerative Colitis Heterogeneity and Identify Patients With Increased Response to Therapy.
    J Crohns Colitis. 2025 Jun 9:jjaf092. doi: 10.1093.
    >> Share

  145. PANES J, Dubinsky MC, Ishiguro Y, Shukla N, et al
    Achievement of long-term treatment goals in upadacitinib-treated patients with moderately to severely active ulcerative colitis: a post hoc analysis of phase 3 trial data.
    J Crohns Colitis. 2025 Jun 9:jjaf095. doi: 10.1093.
    >> Share

  146. BAI J, Bouwknegt DG, Weersma RK, Dijkstra G, et al
    Gene-Environment Interactions in Inflammatory Bowel Disease: A Systematic Review of Human Epidemiologic Studies.
    J Crohns Colitis. 2025;19:jjaf061.
    >> Share

  147. KIRCHGESNER J, Verstockt B, Adamina M, Allin KH, et al
    ECCO Topical Review on Predictive Models on Inflammatory Bowel Disease Disease Course and Treatment Response.
    J Crohns Colitis. 2025;19:jjaf073.
    >> Share

  148. DI VINCENZO F, Quintero MA, Serigado JM, Koru-Sengul T, et al
    Histologic and Endoscopic Findings Are Highly Correlated in a Prospective Cohort of Patients With Inflammatory Bowel Diseases.
    J Crohns Colitis. 2025;19:jjae141.
    >> Share

  149. WIERINGA JW, Esser MJ, den Hartog G, Nicolaie MA, et al
    Impact of immunomodulating medication on maternal Tdap vaccination-induced antibodies in infants.
    J Crohns Colitis. 2025;19:jjaf090.
    >> Share

  150. WEWER MD, Lophaven S, Lakatos PL, Gonczi L, et al
    Long-term disease course of ulcerative colitis in a prospective European population-based inception cohort - an Epi-IBD cohort study.
    J Crohns Colitis. 2025 Jun 3:jjaf089. doi: 10.1093.
    >> Share

  151. EVERHOV AH, Askling J, Soderling J, Halfvarson J, et al
    Cancer Incidence in Patients with Ulcerative Colitis Naive to or Treated with Thiopurine and Targeted Therapies- a cohort study 2007 to 2022 with comparison to the general population.
    J Crohns Colitis. 2025 Jun 2:jjaf091. doi: 10.1093.
    >> Share

    May 2025
  152. VERMEIRE S, Nitcheu J, Gineste P, Flatres A, et al
    Obefazimod in Patients with Moderate-to-Severely Active Ulcerative Colitis: Efficacy and Safety Analysis from the 96-week Open-label Maintenance Phase 2b study.
    J Crohns Colitis. 2025 May 26:jjaf074. doi: 10.1093.
    >> Share

  153. LEHMANN M, Paclik D, Huck A, Arnold A, et al
    Spatial Immune Profiling of Crohn's Disease Fistula Carcinomas - Defining a Distinct Cancer Subtype.
    J Crohns Colitis. 2025 May 26:jjaf086. doi: 10.1093.
    >> Share

  154. SU J, Lartey DA, Zanella G, Hawinkels LJAC, et al
    Therapeutic potential of Janus kinase inhibitors for the management of fibrosis in inflammatory bowel disease.
    J Crohns Colitis. 2025 May 24:jjaf087. doi: 10.1093.
    >> Share

  155. POULSEN A, Alexdottir MS, Riis LB, Ovesen PD, et al
    Serum Biomarkers of Collagen Remodeling are Associated with Intestinal Fibrosis and Differentiates Stenotic from Luminal Crohn's Disease Patients: A Pre- and Post-Resection Longitudinal Study.
    J Crohns Colitis. 2025 May 20:jjaf085. doi: 10.1093.
    >> Share

  156. ARTONE S, Ray S, Williams JJ, Akbulut K, et al
    The angiotensin receptor blocker, losartan, reduces inflammation and fibrosis, and prevents relapse of fibrosis after steroid-induced remission, in mice prone to Crohn's disease-like ileitis.
    J Crohns Colitis. 2025 May 20:jjaf083. doi: 10.1093.
    >> Share

  157. OU W, Wang Y, Xu W, Hua Z, et al
    Restoring Prostacyclin/PGI2-PTGIR Signaling Alleviates Intestinal Fibrosis in Crohn's Disease via Fibroblast-specific YAP/TAZ Inhibition.
    J Crohns Colitis. 2025 May 20:jjaf084. doi: 10.1093.
    >> Share

  158. BOURGONJE AR, Ibing S, Livanos AE, Ganjian DY, et al
    Distinct perturbances in metabolic pathways associate with disease progression in inflammatory bowel disease.
    J Crohns Colitis. 2025 May 18:jjaf082. doi: 10.1093.
    >> Share

  159. KONTOLA K, Ilus T, Huhtala H, Helavirta L, et al
    Risk of colectomy is decreasing among newly diagnosed Finnish ulcerative colitis patients.
    J Crohns Colitis. 2025 May 13:jjaf081. doi: 10.1093.
    >> Share

  160. D'HAENS G, Danese S, Panaccione R, Rubin DT, et al
    Deucravacitinib in Patients With Inflammatory Bowel Disease: 12-Week Efficacy and Safety Results From Three Randomized Phase 2 Studies in Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2025 May 13:jjaf080. doi: 10.1093.
    >> Share

  161. TONTINI GE, Rath T
    Be precise, be reproducible! The emerging role of artificial intelligence in inflammatory bowel disease endoscopy.
    J Crohns Colitis. 2025;19:jjaf046.
    >> Share


  162. Correction to: Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection.
    J Crohns Colitis. 2025;19:jjaf071.
    >> Share

  163. YU M, Si C, Xinjue H, Pan Y, et al
    Biglycan deficiency alleviates intestinal fibrosis through BMP-7-mediated Smad1/5/8 signaling.
    J Crohns Colitis. 2025;19:jjaf065.
    >> Share

  164. SALOMON B, Sudhakar P, Bergemalm D, Andersson E, et al
    Characterization of Inflammatory Bowel Disease Heterogeneity Using Serum Proteomics: A Multicenter Study.
    J Crohns Colitis. 2025;19:jjae169.
    >> Share


  165. Correction to: Autoimmune Pancreatitis in Patients with Inflammatory Bowel Disease: A Real-World Multicentre Collaborative ECCO CONFER Study.
    J Crohns Colitis. 2025;19:jjaf077.
    >> Share

  166. GEYL S, Jacques J, Anneraud A, Chaussade S, et al
    Endoscopic submucosal dissection for visible dysplasia in inflammatory bowel disease: a nationwide multicenter cohort from the GETAID and the SFED.
    J Crohns Colitis. 2025;19:jjaf057.
    >> Share

  167. VERSTOCKT S, Sabino J, Ferrante M, Vermeire S, et al
    Serum extracellular RNAs as a noninvasive approach to differentiate inflammatory bowel disease subtypes: a proof-of-concept study.
    J Crohns Colitis. 2025;19:jjaf047.
    >> Share

  168. DUBINSKY MC, Wu J, McDonnell A, Lazin K, et al
    Low Incidence of Macular Edema and Other Ocular Events in the Etrasimod Development Program.
    J Crohns Colitis. 2025;19:jjae173.
    >> Share

  169. THOMAS DR, Huangfu G, Yeaman F, Sukudom S, et al
    Association between inflammatory bowel disease, current therapies, and cardiovascular events: a review and meta-analysis of data from 2.2 million individuals.
    J Crohns Colitis. 2025 May 7:jjaf078. doi: 10.1093.
    >> Share

  170. GOODWIN SW, Haan M, Yuan Y, Wilk P, et al
    Spatial mapping and geographic variation of inflammatory bowel disease in Canada: A population-based study.
    J Crohns Colitis. 2025 May 6:jjaf079. doi: 10.1093.
    >> Share

  171. MELON-ARDANAZ E, Veny M, Corraliza AM, Gudino V, et al
    Differential effects of tofacitinib on macrophage activation contribute to lack of response in ulcerative colitis patients.
    J Crohns Colitis. 2025 May 5:jjaf076. doi: 10.1093.
    >> Share

  172. DOLINGER MT, Aronskyy I, Spencer EA, Pittman N, et al
    Early Intestinal Ultrasound Response to Biologic and Small Molecule Therapy is Accurate to Predict Treat-To-Target Endoscopic Outcomes in Children with Ulcerative Colitis: Results from the Prospective Super Sonic-UC Study.
    J Crohns Colitis. 2025 May 2:jjaf075. doi: 10.1093.
    >> Share

    April 2025
  173. LINGGI B, Salas A, Steere B, Verstockt B, et al
    Expert Recommendations to Standardise Transcriptomic Analysis in Inflammatory Bowel Disease Clinical Trials.
    J Crohns Colitis. 2025 Apr 29:jjaf068. doi: 10.1093.
    >> Share

  174. LI JR, Yang BL, Zhu ZX, Gong YX, et al
    Development and psychometric validation of a patient-reported outcome measure scale for Crohn's disease anorectal stricture.
    J Crohns Colitis. 2025 Apr 24:jjaf072. doi: 10.1093.
    >> Share

  175. JOHNSON AM, Askar M, Belani S, Khan A, et al
    A Multicenter Study of the Real-World Effectiveness and Safety of Risankizumab in Crohn's Disease.
    J Crohns Colitis. 2025 Apr 24:jjaf070. doi: 10.1093.
    >> Share

  176. ALAJMI A, Yuan Y, Solitano V, Rosenfeld DEC, et al
    5-Aminosalicylates for non-Surgical Patients With Active or Quiescent Crohn's Disease: An Overview Of Systematic Reviews (Umbrella Review).
    J Crohns Colitis. 2025 Apr 21:jjaf069. doi: 10.1093.
    >> Share

  177. VIEUJEAN S, Peyrin-Biroulet L
    Triple Biologic Therapy for Refractory Crohn's Disease.
    J Crohns Colitis. 2025 Apr 19:jjaf067. doi: 10.1093.
    >> Share

  178. NIELSEN VW, Attauabi M, Holgersen N, Madsen GR, et al
    Hidradenitis suppurativa among patients with new-onset inflammatory bowel disease - Results from the IBD Prognosis Study.
    J Crohns Colitis. 2025 Apr 19:jjaf066. doi: 10.1093.
    >> Share

  179. PERTSINIDOU E, Salomon B, Bergemalm D, Salihovic S, et al
    Anti-integrin alphavbeta6 IgG antibody as a diagnostic and prognostic marker in ulcerative colitis: A cross-sectional and longitudinal study defining a specific disease phenotype.
    J Crohns Colitis. 2025 Apr 19:jjaf062. doi: 10.1093.
    >> Share

  180. COLOMBEL JF, Sandborn WJ, Schreiber S, Danese S, et al
    Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Crohn's Disease and Ulcerative Colitis: 2-Year Results from Open-Label Extensions of Two Randomized Controlled Trials (LIBERTY).
    J Crohns Colitis. 2025 Apr 17:jjaf060. doi: 10.1093.
    >> Share

  181. VERSTOCKT B, Alsoud D, van Oostrom J, Verstockt S, et al
    Drug tissue concentration and STAT3 modulation as determinants of tofacitinib response in ulcerative colitis.
    J Crohns Colitis. 2025 Apr 17:jjaf063. doi: 10.1093.
    >> Share

  182. FUENTES-VALENZUELA E, Baston-Rey I, Garcia-Alonso FJ, Elosua A, et al
    Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study of GETECCU.
    J Crohns Colitis. 2025 Apr 10:jjaf058. doi: 10.1093.
    >> Share

  183. BATTAT R, Kandi S, Lacerda AP, Levine P, et al
    Association of Bile Acid Diarrhea with Symptoms and Disease Activity in Crohn's Disease: Post-Hoc Clinical Trial Analysis of Serum 7a-hydroxy-4cholestern-3-one, C4, in Patients with Active Crohn's Disease.
    J Crohns Colitis. 2025 Apr 9:jjaf053. doi: 10.1093.
    >> Share

  184. WONG ECL, Dulai PS, Marshall JK, Laroux S, et al
    Use of Modified Multiplier of the Simple Endoscopic Score for Crohn's Disease Endoscopic Improvement Thresholds Enhances Effect Size Differentiation Between Adalimumab Versus Placebo: A Post Hoc Analysis of the EXTEND Trial.
    J Crohns Colitis. 2025;19:jjae171.
    >> Share

  185. RASMUSSEN J, Norgard BM, Boggild H, Qvist N, et al
    Labor Market Participation and Income in Patients With Inflammatory Bowel Disease Onset Before Young Adulthood-The Role of Disease Severity and Mental Health.
    J Crohns Colitis. 2025;19:jjae165.
    >> Share

  186. MITROVA K, Kostrejova M, Zdychyncova K, Lukas M, et al
    Effect of tofacitinib exposure in utero and during breastfeeding on the immune status of exposed child.
    J Crohns Colitis. 2025;19:jjaf049.
    >> Share

  187. REYNOLDS DP, Chalder T, Henderson C
    The mediating role of psychological inflexibility on internalised stigma and patient outcomes in a sample of adults with inflammatory bowel disease.
    J Crohns Colitis. 2025 Apr 1:jjaf055. doi: 10.1093.
    >> Share

  188. REINISCH W, Loftus EV Jr, Schreiber S, Rubin DT, et al
    Corticosteroid-Sparing Effects of Risankizumab Efficacy and Safety in Patients With Moderately to Severely Active Ulcerative Colitis.
    J Crohns Colitis. 2025 Apr 1:jjaf025. doi: 10.1093.
    >> Share

  189. ISHIKAWA D, Watanabe H, Nomura K, Zhang X, et al
    Patient-donor similarity and donor-derived species contribute to the outcome of faecal microbiota transplantation for ulcerative colitis.
    J Crohns Colitis. 2025 Apr 1:jjaf054. doi: 10.1093.
    >> Share

  190. NOVIELLO D, Chaparro M, Vigano C, Blesl A, et al
    Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicentre retrospective cohort study.
    J Crohns Colitis. 2025 Apr 1:jjaf056. doi: 10.1093.
    >> Share

    March 2025
  191. BOKEMEYER B, Plachta-Danielzik S, Gilman E, Howaldt S, et al
    Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study.
    J Crohns Colitis. 2025 Mar 27:jjaf052. doi: 10.1093.
    >> Share

  192. BOKEMEYER B, Plachta-Danielzik S, Gilman E, di Giuseppe R, et al
    Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn's disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment.
    J Crohns Colitis. 2025 Mar 25:jjaf051. doi: 10.1093.
    >> Share

  193. INNOCENTI T, Rocco C, Balena E, Petrucci G, et al
    The use of International Bowel Ultrasound Segmental Activity Score (IBUS-SAS) in patients with ulcerative colitis: applicability and comparison with other ultrasound scores.
    J Crohns Colitis. 2025 Mar 24:jjaf050. doi: 10.1093.
    >> Share

  194. UMAR N, Wambua S, Harvey P, Cusworth S, et al
    Development and validation of a risk prediction tool for the diagnosis of inflammatory bowel disease in patients presenting in primary care with abdominal symptoms.
    J Crohns Colitis. 2025 Mar 18:jjaf044. doi: 10.1093.
    >> Share

  195. LEITE-GOMES E, C Silva M, M Dias A, Fernandes A, et al
    T cell branched glycosylation as a mediator of colitis-associated colorectal cancer progression: a potential new risk biomarker in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Mar 15:jjaf043. doi: 10.1093.
    >> Share

  196. JAIRATH V, Narula N, Ungaro RC, Romo Bautista I, et al
    Novel Outcomes in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Mar 13:jjaf040. doi: 10.1093.
    >> Share

  197. CHHIBBA T, Gros B, King JA, Windsor JW, et al
    Environmental Risk Factors of Inflammatory Bowel Disease: Towards a Strategy of Preventative Health.
    J Crohns Colitis. 2025 Mar 11:jjaf042. doi: 10.1093.
    >> Share

  198. ABUSHAMMA S, Yadete T, Nero N, Falloon K, et al
    Definitions, Diagnosis and Management of Postoperative Recurrence in Crohn's Disease Patients with Permanent Ileostomy - A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2025 Mar 10:jjaf041. doi: 10.1093.
    >> Share

  199. SHEN M, Gao S, Zhu R, Wang W, et al
    Multimodal Metagenomic Analysis Reveals Microbial InDels as Superior Biomarkers for Pediatric Crohn's Disease.
    J Crohns Colitis. 2025 Mar 7:jjaf039. doi: 10.1093.
    >> Share

  200. KUMARALINGAM L, Le May K, Dang VB, Alavi J, et al
    Artificial intelligence-assisted approach to assessing bowel wall thickness in pediatric inflammatory bowel disease using intestinal ultrasound images.
    J Crohns Colitis. 2025 Mar 7:jjaf037. doi: 10.1093.
    >> Share

  201. YE S, Fu T, Tu Y, Wellens J, et al
    Higher Dietary Glycemic Index, but not Glycemic Load, is Associated with Increased Risk of Ulcerative Colitis: A Prospective Cohort Study.
    J Crohns Colitis. 2025 Mar 6:jjaf036. doi: 10.1093.
    >> Share

  202. YAN Y, Tian L, Zhao Y, Xuan B, et al
    Bacteroides fragilis Toxin Suppresses METTL3-Mediated m6A Modification in Macrophage to Promote Inflammatory Bowel Disease.
    J Crohns Colitis. 2025;19:jjae179.
    >> Share


  203. Correction to: P0722 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension.
    J Crohns Colitis. 2025;19:jjaf045.
    >> Share

  204. SANDS BE, Leung Y, Rubin DT, Gecse KB, et al
    Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program.
    J Crohns Colitis. 2025;19:jjae150.
    >> Share

  205. KUNKLE B, Singh H, Abraham D, Asamoah N, et al
    Independent Predictors of 90-Day Readmission in Patients with Inflammatory Bowel Disease: A Nationwide Retrospective Study.
    J Crohns Colitis. 2025 Mar 3:jjaf034. doi: 10.1093.
    >> Share

  206. MADSEN GR, Wilkens R, Attauabi M, Ilvemark JFKF, et al
    Intestinal Ultrasound as a Prognostic Tool in New-Onset Ulcerative Colitis - A Copenhagen IBD Cohort Study.
    J Crohns Colitis. 2025 Mar 1:jjaf033. doi: 10.1093.
    >> Share

    February 2025
  207. STEPHENS M, Keane K, Roizes S, Defaye M, et al
    Uncovering the therapeutic potential of anti-tuberculoid agent Isoniazid in a model of microbial-driven Crohn's Disease.
    J Crohns Colitis. 2025 Feb 23:jjaf032. doi: 10.1093.
    >> Share

  208. TYRODE G, Riviere P, Sebastian S, Poullenot F, et al
    Systematic review: severe endoscopic lesions in inflammatory bowel disease.
    J Crohns Colitis. 2025 Feb 19:jjaf029. doi: 10.1093.
    >> Share

  209. CARDINALE CJ, Liu Y, Kevadia A, Strong A, et al
    The ulcerative colitis risk gene adenylyl cyclase 7 restrains the T helper 2 phenotype and Class II antigen presentation.
    J Crohns Colitis. 2025 Feb 17:jjaf030. doi: 10.1093.
    >> Share

  210. VAN LINSCHOTEN RCA, van Leeuwen N, van Klaveren D, Pierik PMJ, et al
    Prevalence, incidence and mortality of inflammatory bowel disease in the Netherlands: development and external validation of machine learning models.
    J Crohns Colitis. 2025 Feb 13:jjaf017. doi: 10.1093.
    >> Share

  211. CREMER A, Rosewick N, Kelsey M, Trepo E, et al
    A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Feb 13:jjaf026. doi: 10.1093.
    >> Share

  212. ZHANG X, Norgard BM, Garvik OS, Nielsen J, et al
    Adverse maternal outcomes after vaginal versus caesarean delivery in women with Crohn's disease and prior perianal surgery: A population-based study.
    J Crohns Colitis. 2025 Feb 12:jjaf028. doi: 10.1093.
    >> Share

  213. HONAP S, Peyrin-Biroulet L
    Disease-Modifying Anti-Inflammatory Drugs: Shaping the Future of Inflammatory Bowel Disease Care.
    J Crohns Colitis. 2025 Feb 8:jjaf027. doi: 10.1093.
    >> Share

  214. GE C, Lu Y, Shen Z, Lu Y, et al
    Machine learning and metabolomics identify biomarkers associated with the disease extent of ulcerative colitis.
    J Crohns Colitis. 2025 Feb 4:jjaf020. doi: 10.1093.
    >> Share

  215. DAL BUONO A, Faita F, Armuzzi A, Jairath V, et al
    Assessment of activity and severity of inflammatory bowel disease in cross-sectional imaging techniques: a systematic review.
    J Crohns Colitis. 2025 Feb 4:jjaf023. doi: 10.1093.
    >> Share

  216. URQUHART SA, Pallipamu N, Voruganti HV, Baraskar B, et al
    Non-Conventional Dysplasia in Patients with Inflammatory Bowel Disease and Colorectal Adenocarcinoma: A Case-Cohort Study.
    J Crohns Colitis. 2025 Feb 4:jjaf022. doi: 10.1093.
    >> Share


  217. Correction to: Ulcerative Colitis Severity Classification and Localized Extent (UC-SCALE): An Artificial Intelligence Scoring System for a Spatial Assessment of Disease Severity in Ulcerative Colitis.
    J Crohns Colitis. 2025;19:jjaf031.
    >> Share

  218. NANI MF, Pagano E, De Cicco P, Lucariello G, et al
    Pharmacological Inhibition of N-Acylethanolamine Acid Amidase (NAAA) Mitigates Intestinal Fibrosis Through Modulation of Macrophage Activity.
    J Crohns Colitis. 2025;19:jjae132.
    >> Share

  219. ZHANG J, Mengli Y, Zhang T, Song X, et al
    Deficiency in Epithelium RAD50 Aggravates UC via IL-6-Mediated JAK1/2-STAT3 Signaling and Promotes Development of Colitis-Associated Cancer in Mice.
    J Crohns Colitis. 2025;19:jjae134.
    >> Share

  220. LAHARIE D, Vuitton L, Bourreille A, Bouhnik Y, et al
    The Groupe d'Etude sur les Affections Inflammatoires Digestives (GETAID): 40 Years of a Family Story in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025;19:jjae122.
    >> Share

  221. AL-SHEIKH M, Ankersen DV, Olsen J, Spanggaard M, et al
    The Costs of Home Monitoring by Telemedicine vs Standard Care for Inflammatory Bowel Diseases-A Danish Register-Based, 5-Year Follow-up Study.
    J Crohns Colitis. 2025;19:jjae120.
    >> Share

    January 2025
  222. KUROKI T, Maeda Y, Kudo SE, Ogata N, et al
    Combination of white-light imaging based and narrow-band imaging based artificial intelligence models during colonoscopy in patients with ulcerative colitis.
    J Crohns Colitis. 2025 Jan 31:jjaf014. doi: 10.1093.
    >> Share

  223. BRETON J, Tu V, Tanes C, Wilson N, et al
    A pro-inflammatory diet is associated with growth and virulence of Escherichia coli in pediatric Crohn's disease.
    J Crohns Colitis. 2025 Jan 31:jjaf018. doi: 10.1093.
    >> Share

  224. GISBERT JP, Chaparro M
    Janus kinase inhibitors in the management of acute severe ulcerative colitis: a comprehensive review.
    J Crohns Colitis. 2025 Jan 31:jjaf021. doi: 10.1093.
    >> Share

  225. VISSER E, Luberto A, Heuthorst L, Hompes R, et al
    The Impact of Advanced Medical Therapies on Time to Resection and Colorectal Cancer Outcomes in Ulcerative Colitis Patients Undergoing Colectomy.
    J Crohns Colitis. 2025 Jan 23:jjaf015. doi: 10.1093.
    >> Share

  226. GONG W, Liu P, Liu J, Li Y, et al
    GSDMB modulates intestinal epithelial homeostasis via regulating hyperactive unfolded protein response in Crohn's disease.
    J Crohns Colitis. 2025 Jan 20:jjaf012. doi: 10.1093.
    >> Share

  227. CANETE F, Vela E, Calafat M, Piera J, et al
    Severe obesity, a susceptibility factor for developing inflammatory bowel disease. Results of a population-based study.
    J Crohns Colitis. 2025 Jan 18:jjaf010. doi: 10.1093.
    >> Share

  228. CHHIBBA T, Sachdeva K, Ananthakrishnan AN
    Assessment and Reporting of Extraintestinal Manifestations and Fatigue in Phase 3 Inflammatory Bowel Disease Clinical Trials.
    J Crohns Colitis. 2025 Jan 18:jjaf009. doi: 10.1093.
    >> Share

  229. ALLOCCA M, D'Amico F, Fiorino G, Jairath V, et al
    Systematic Review on definitions of Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Jan 18:jjaf011. doi: 10.1093.
    >> Share

  230. MALMQUIST M, Voghera S, Berg S, Saalman R, et al
    Childhood-onset inflammatory bowel disease and chronic non-bacterial osteomyelitis: A Swedish nationwide cohort study 2002-2022.
    J Crohns Colitis. 2025 Jan 13:jjaf007. doi: 10.1093.
    >> Share

  231. WONG ECL, Dulai PS, Marshall JK, Jairath V, et al
    Improvement in Serum Eosinophilia is Observed in Clinical Responders to Ustekinumab but not Adalimumab in Inflammatory Bowel Disease.
    J Crohns Colitis. 2025 Jan 13:jjaf006. doi: 10.1093.
    >> Share

  232. BALARAJAH S, Martinez-Gili L, Alexander JL, Mullish BH, et al
    Diverse Phenotypes, Consistent Treatment: A Study of 30 997 South Asian and White Inflammatory Bowel Disease Patients Using the UK Inflammatory Bowel Disease BioResource.
    J Crohns Colitis. 2025;19:jjae186.
    >> Share

  233. KABOUB K, Abu-Taha H, Arrouasse J, Shaham-Barda E, et al
    Discordant Effects of Janus Kinase Inhibition Ex Vivo on Inflammatory Responses in Colonic Compared to Ileal Mucosa.
    J Crohns Colitis. 2025;19:jjae117.
    >> Share

  234. PANACCIONE R, Louis E, Colombel JF, D'Haens G, et al
    Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.
    J Crohns Colitis. 2025;19:jjaf005.
    >> Share

  235. ANGYAL D, Gonczi L, Balogh F, Wetwittayakhlang P, et al
    Inflammatory bowel diseases in the elderly population: epidemiology, long-term disease course, surgery rates, and biological use-data from the Veszprem county cohort between 1977 and 2020.
    J Crohns Colitis. 2025;19:jjaf003.
    >> Share

  236. DE GREGORIO M, Winata LS, Hartley I, Behrenbruch CC, et al
    A new protocolized treatment strategy optimizing medical and surgical care leads to improved healing of Crohn's perianal fistulas.
    J Crohns Colitis. 2025;19:jjae199.
    >> Share

  237. CARTLIDGE P, Ho GT, Kalla R
    Decoding the proteomic landscape of inflammatory bowel disease.
    J Crohns Colitis. 2025;19:jjaf008.
    >> Share

  238. MCGING JJ, Serres S, Nicholas R, Gupta A, et al
    Deconditioning in quiescent Crohn's Disease patients with heightened fatigue perception.
    J Crohns Colitis. 2025 Jan 9:jjae194. doi: 10.1093.
    >> Share

  239. MUNSTER LJ, Hanna LN, Hart AL, Tozer PJ, et al
    Diagnosing Crohn's Disease in Presumed Cryptoglandular Perianal Fistulas: An Expert Delphi Consensus on Early Identification of Patients at Risk of Crohn's Disease in Perianal Fistulas (PREFAB).
    J Crohns Colitis. 2025 Jan 7:jjaf002. doi: 10.1093.
    >> Share

  240. ABDALLA S, Benoist S, Maggiori L, Lefevre JH, et al
    Durable remission after ileocolic resection for Crohn's disease is achievable in selected patients. Long-term results of a prospective multicentric cohort study of the GETAID Chirurgie.
    J Crohns Colitis. 2025 Jan 7:jjae193. doi: 10.1093.
    >> Share

  241. JORISSEN T, Fierens L, Bosmans H, Verstockt B, et al
    Radiation exposure in patients with inflammatory bowel disease.
    J Crohns Colitis. 2025 Jan 6:jjaf001. doi: 10.1093.
    >> Share

  242. PRETO AJ, Chanana S, Ence D, Healy MD, et al
    Multi-omics data integration identifies novel biomarkers and patient subgroups in inflammatory bowel disease.
    J Crohns Colitis. 2025 Jan 4:jjae197. doi: 10.1093.
    >> Share

  243. VAN OOSTROM J, Hanzel J, Verstockt B, Singh S, et al
    Anti-TNF Non-Response in Ulcerative Colitis: Correcting for Mucosal Drug Exposure Reveals Distinct Cytokine Profiles.
    J Crohns Colitis. 2025 Jan 2:jjae200. doi: 10.1093.
    >> Share

  244. PUGA-TEJADA M, Majumder S, Maeda Y, Zammarchi I, et al
    Artificial intelligence-enabled histology exhibits comparable accuracy to pathologists in assessing histological remission in Ulcerative Colitis: a systematic review, meta-analysis and meta-regression.
    J Crohns Colitis. 2025 Jan 1:jjae198. doi: 10.1093.
    >> Share

    December 2024
  245. ZHAO M, Larsen L, Dige A, Poulsen A, et al
    Clinical outcomes after first-line anti-TNF treatment of patients with inflammatory bowel disease - a prospective multicenter cohort study.
    J Crohns Colitis. 2024 Dec 19:jjae192. doi: 10.1093.
    >> Share

  246. BUOSO E, Masi M, Limosani RV, Fagiani F, et al
    Disruption of epithelial barrier integrity via altered GILZ/c-Rel/RACK1 signaling in inflammatory bowel disease (IBD).
    J Crohns Colitis. 2024 Dec 18:jjae191. doi: 10.1093.
    >> Share

  247. BENCARDINO S, Allocca M, Furfaro F, D'Amico F, et al
    Multiple Ileal and Colonic Stenoses: Is It Always Crohn's Disease?
    J Crohns Colitis. 2024 Dec 16:jjae174. doi: 10.1093.
    >> Share

  248. QURAISHI MN, Cheesbrough J, Rimmer P, Mullish BH, et al
    Open label vancomycin in primary sclerosing cholangitis-inflammatory bowel disease: improved colonic disease activity and associations with changes in host-microbiome-metabolomic signatures.
    J Crohns Colitis. 2024 Dec 14:jjae189. doi: 10.1093.
    >> Share

  249. GROS B, Constantine-Cooke N, Kennedy J, Elford AT, et al
    Tofacitinib versus Vedolizumab Among Bio-naive Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison.
    J Crohns Colitis. 2024 Dec 11:jjae188. doi: 10.1093.
    >> Share

  250. GROS B, Peraza J, Bassi M, Sleiman J, et al
    Disparities in gender and race representation among authors of inflammatory bowel disease clinical trials.
    J Crohns Colitis. 2024 Dec 7:jjae184. doi: 10.1093.
    >> Share

  251. GUTIERREZ BECKER B, Fraessle S, Yao H, Luscher J, et al
    Ulcerative Colitis Severity Classification and Localised Extent (UC-SCALE): An Artificial Intelligence scoring system for a spatial assessment of disease severity in Ulcerative Colitis.
    J Crohns Colitis. 2024 Dec 7:jjae187. doi: 10.1093.
    >> Share

  252. WILEMAN V, Chilcot J, Norton C, Hart A, et al
    Modifiable psychological factors are associated with clusters of pain, fatigue, faecal incontinence and IBS-type symptoms in inflammatory bowel disease: a latent profile analysis.
    J Crohns Colitis. 2024 Dec 5:jjae183. doi: 10.1093.
    >> Share

    November 2024
  253. YERUSHALMY-FELER A, Spencer EA, Dolinger MT, Suskind DL, et al
    Upadacitinib for Induction of Remission in Pediatric Ulcerative Colitis: An International Multi?center Study.
    J Crohns Colitis. 2024 Nov 28:jjae182. doi: 10.1093.
    >> Share

  254. SINONQUEL P, Lenfant M, Eelbode T, Watanabe H, et al
    Development of an automated tool for the estimation of histological remission in ulcerative colitis using single wavelength endoscopy technology.
    J Crohns Colitis. 2024 Nov 27:jjae180. doi: 10.1093.
    >> Share

  255. LIMDI JK, Rhodes S, Liu E, Kuriakose Kuzhiyanjal AJ, et al
    Knowledge, Values and Preferences regarding Contraceptive Choices among Women living with Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Nov 27:jjae181. doi: 10.1093.
    >> Share


  256. Correction to: Influence of Vitamin D Receptor Signalling and Vitamin D on Colonic Epithelial Cell Fate Decisions in Ulcerative Colitis.
    J Crohns Colitis. 2024 Nov 26:jjae168. doi: 10.1093.
    >> Share

  257. MANCHERON A, Dumas A, Nion Larmurier I, Landman C, et al
    Development and Validation of a Sexual Quality of Life Score for Youths with Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Nov 22:jjae175. doi: 10.1093.
    >> Share

  258. DE-LA-CRUZ JL, Gomollon F, Louro J, Lopez Perez J, et al
    Impact Of Hladqa1*05 And Hladqa1*03 On Safety And Loss Of Response To Anti-Tnf In Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Nov 21:jjae178. doi: 10.1093.
    >> Share

  259. JATKOWSKA A, White B, Gkikas K, Seenan JP, et al
    Partial Enteral Nutrition in the Management of Crohn's Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2024 Nov 20:jjae177. doi: 10.1093.
    >> Share

  260. ATTAUABI M, Madsen GR, Bendtsen F, Seidelin JB, et al
    Incidence, disease burden and clinical presentation of patients newly diagnosed with inflammatory bowel disease in a population-based inception cohort.
    J Crohns Colitis. 2024 Nov 20:jjae176. doi: 10.1093.
    >> Share

  261. HOLTEN KA, Bernklev T, Opheim R, Olsen BC, et al
    Fatigue in patients with inflammatory bowel disease in remission one year after diagnosis (the IBSEN III study).
    J Crohns Colitis. 2024 Nov 11:jjae170. doi: 10.1093.
    >> Share

  262. VERMEIRE S, Sands BE, Peyrin-Biroulet L, D'Haens GR, et al
    Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials.
    J Crohns Colitis. 2024;18:1780-1794.
    >> Share

  263. POULSEN A, Ovesen PD, Lu C, Bettenworth D, et al
    Serum Extracellular Matrix Molecules and Their Fragments as Biomarkers of Inflammation and Fibrosis in Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2024;18:1894-1934.
    >> Share

  264. REENAERS C, Enea D, Nachury M, Laharie D, et al
    Impact of histological remission for predicting clinical relapse in Crohn's disease: a post-hoc analysis of the prospective STORI cohort.
    J Crohns Colitis. 2024 Nov 2:jjae167. doi: 10.1093.
    >> Share

  265. VAN GAALEN MA, van Pieterson M, Waaijenberg P, Kindermann A, et al
    Effectiveness of transitional care in Inflammatory Bowel Disease; Development, Validation, and Initial outcomes of a Transition Success Score.
    J Crohns Colitis. 2024 Nov 2:jjae166. doi: 10.1093.
    >> Share

  266. ATREYA R, Ferrante M, Panaccione R, Feagan B, et al
    Risankizumab Is Associated With Normalization of Biomarkers in Patients With Crohn's Disease: Results From the Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.
    J Crohns Colitis. 2024 Nov 1:jjae164. doi: 10.1093.
    >> Share

    October 2024
  267. DELEN S, Jaghult S, Blumenstein I, Pouillon L, et al
    Framework of IBD Care Delivery Across Ages.
    J Crohns Colitis. 2024;18.
    >> Share

  268. CARON B, Honap S, Peyrin-Biroulet L
    Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies.
    J Crohns Colitis. 2024;18.
    >> Share

  269. VUIJK SA, Camman AE, de Ridder L
    Considerations in Paediatric and Adolescent Inflammatory Bowel Disease.
    J Crohns Colitis. 2024;18.
    >> Share

  270. SOUSA P, Gisbert JP, Julsgaard M, Selinger CP, et al
    Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review.
    J Crohns Colitis. 2024;18.
    >> Share

  271. CARBERY I, Selinger CP, Todd O, Sebastian S, et al
    Considerations on Multimorbidity and Frailty in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18.
    >> Share

  272. BREDERO QM, Fleer J, Blom DM, Bourgonje AR, et al
    The substantial role of sleep, stress and physical activity in persistent high levels of fatigue in patients with inflammatory bowel disease: A longitudinal trajectory study.
    J Crohns Colitis. 2024 Oct 26:jjae163. doi: 10.1093.
    >> Share

  273. ZILBERSTEIN NF, Engen PA, Swanson GR, Naqib A, et al
    The Bidirectional Effects of Periodontal Disease and Oral Dysbiosis on Gut Inflammation in Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Oct 24:jjae162. doi: 10.1093.
    >> Share

  274. GORELIK Y, Ghersin I, Lujan R, Shlon D, et al
    GLP-1 analog use is associated with improved disease course in inflammatory bowel disease: a report from the Epi-IIRN.
    J Crohns Colitis. 2024 Oct 23:jjae160. doi: 10.1093.
    >> Share

  275. LONGMAN RS
    Multiomics Resolves Regulatory Mechanisms in a Diverse Cohort of Crohn's Disease.
    J Crohns Colitis. 2024 Oct 22:jjae154. doi: 10.1093.
    >> Share

  276. GOREN I, Fallek Boldes O, Boldes T, Knyazev O, et al
    Post-Discharge Outcomes of Elderly Patients Hospitalized for Inflammatory Bowel Disease Flare Complicated by Clostridioides difficile Infection.
    J Crohns Colitis. 2024 Oct 21:jjae161. doi: 10.1093.
    >> Share

  277. ATREYA R, Neurath MF
    IL-23R-Specific Chimeric Antigen Receptor Tregs in Crohn's Disease: Dawn of a Cellular Immunotherapeutic Era?
    J Crohns Colitis. 2024 Oct 21:jjae159. doi: 10.1093.
    >> Share

  278. UCHIYAMA K, Takagi T, Mizushima K, Hirai Y, et al
    Mucosal cytokine expression associated with deep endoscopic mucosal healing in ulcerative colitis.
    J Crohns Colitis. 2024 Oct 16:jjae158. doi: 10.1093.
    >> Share

  279. DERKS MEW, Te Groen M, van Lierop LMA, Murthy S, et al
    Management of Colorectal Neoplasia in IBD Patients: Current Practice and Future Perspectives.
    J Crohns Colitis. 2024;18:1726-1735.
    >> Share

  280. FIERENS L, Carney N, Novacek G, van der Woude CJ, et al
    A Core Outcome Set for Inflammatory Bowel Diseases: Development and Recommendations for Implementation in Clinical Practice Through an International Multi-stakeholder Consensus Process.
    J Crohns Colitis. 2024;18:1583-1595.
    >> Share

  281. NOBLE A, Adams A, Nowak J, Cheng G, et al
    The circulating methylome in childhood-onset inflammatory bowel disease.
    J Crohns Colitis. 2024 Oct 4:jjae157. doi: 10.1093.
    >> Share

  282. WANG J, Guay H, Chang D
    Crohn's disease and ulcerative colitis share two molecular subtypes with different mechanisms and drug response.
    J Crohns Colitis. 2024 Oct 3:jjae152. doi: 10.1093.
    >> Share

    September 2024
  283. ARRAS W, Breugelmans T, Oosterlinck B, De Man JG, et al
    The intestinal mucin isoform landscape reveals region-specific biomarker panels for inflammatory bowel disease patient stratification.
    J Crohns Colitis. 2024 Sep 27:jjae155. doi: 10.1093.
    >> Share

  284. JOHANSEN MP, Wewer MD, Krarup PM, Burisch J, et al
    Cancer characteristics, prognoses and mortality of colorectal cancer in patients with Crohn's disease - A Danish nationwide cohort study, 2009-2019.
    J Crohns Colitis. 2024 Sep 26:jjae153. doi: 10.1093.
    >> Share


  285. Corrigendum: Darvadstrocel for Complex Perianal Fistulas in Japanese Adults with Crohn's Disease: A Phase 3 Study.
    J Crohns Colitis. 2024 Sep 25:jjae149. doi: 10.1093.
    >> Share

  286. KALOGEROPOULOU M, Karaivazoglou K, Konstantopoulou G, Vinni E, et al
    The impact of group cognitive behavioral psychotherapy on disease severity and psychosocial functioning in patients with inflammatory bowel disease: a randomized controlled study.
    J Crohns Colitis. 2024 Sep 24:jjae144. doi: 10.1093.
    >> Share

  287. KABIR M, East JE
    Preventing Post-Colonoscopy Colorectal Cancer in Inflammatory Bowel Disease-"The Big Five".
    J Crohns Colitis. 2024 Sep 20:jjae140. doi: 10.1093.
    >> Share

  288. SAMNANI S, Wong ECL, Hamam H, Dulai PS, et al
    Outcomes of patients with prior biologic intolerance are better than those with biologic failure in clinical trials of inflammatory bowel disease.
    J Crohns Colitis. 2024 Sep 20:jjae151. doi: 10.1093.
    >> Share

  289. MUNSTER LJ, Pronk AJM, Mundt MW, Hompes R, et al
    Prolonged time to diagnosis of Crohn's disease in patients with perianal fistulas negatively affects long-term outcomes.
    J Crohns Colitis. 2024 Sep 19:jjae146. doi: 10.1093.
    >> Share

  290. BEN-HORIN S, Salomon N, Yanai H, Kopylov U, et al
    Letter: Change in bowel urgency in active ulcerative colitis patients treated with Curcumin-QingDai (CurQD): A post-hoc analysis of a randomized placebo-controlled trial.
    J Crohns Colitis. 2024 Sep 16:jjae147. doi: 10.1093.
    >> Share

  291. PARIGI TL, Massimino L, Carini A, Gabbiadini R, et al
    Prevalence, characteristics, management, and outcomes of difficult-to-treat inflammatory bowel disease.
    J Crohns Colitis. 2024 Sep 12:jjae145. doi: 10.1093.
    >> Share

  292. CUI Y, David M, Bouchareychas L, Rouquier S, et al
    IL23R-specific CAR Tregs for the treatment of Crohn's disease.
    J Crohns Colitis. 2024 Sep 10:jjae135. doi: 10.1093.
    >> Share

  293. DUAN S, Chen P, Liang C, Zhang Y, et al
    Comparative Efficacy of Novel Biologics, Antitumour Necrosis Factor Agents, and Immunomodulators to Prevent Postoperative Recurrence in Crohn's Disease: A Systematic Review and Network Meta-analysis.
    J Crohns Colitis. 2024 Sep 9:jjae143. doi: 10.1093.
    >> Share

  294. AL SULAIS E, Louis E, Bokemeyer B, Gecse KB, et al
    Differences in the Adverse Event Burden of Corticosteroid Use in Inflammatory Bowel Disease as Reported Between Adverse Event Reporting Systems and a Patient Questionnaire.
    J Crohns Colitis. 2024 Sep 7:jjae138. doi: 10.1093.
    >> Share

  295. MOUTSOGLOU D, Syal A, Lopez S, Nelson EC, et al
    Novel Microbial Engraftment Trajectories following Microbiota Transplantation Therapy in Ulcerative Colitis.
    J Crohns Colitis. 2024 Sep 6:jjae142. doi: 10.1093.
    >> Share

  296. PINTO S, Sajbenova D, Beninca E, Nooij S, et al
    Dynamics of Gut Microbiota after Fecal Microbiota Transplantation in Ulcerative Colitis: Success Linked to Control of Prevotellaceae.
    J Crohns Colitis. 2024 Sep 3:jjae137. doi: 10.1093.
    >> Share

  297. VERSTOCKT B
    VIBRATO's Symphony: Orchestrating Biomarker Harmony for Ritlecitinib in UC Therapy.
    J Crohns Colitis. 2024;18:1359-1360.
    >> Share

  298. YOUSSEF M, Hossein-Javaheri N, Hoxha T, Mallouk C, et al
    Work Productivity Impairment in Persons with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2024;18:1486-1504.
    >> Share

    August 2024
  299. PANACCIONE R, Ma C, Jairath V, Dignass A, et al
    Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials.
    J Crohns Colitis. 2024 Aug 30:jjae128. doi: 10.1093.
    >> Share

  300. JURICKOVA I, Dreskin BW, Angerman E, Bonkowski E, et al
    Eicosatetraynoic Acid Regulates Pro-Fibrotic Pathways in an Induced Pluripotent Stem Cell Derived Macrophage:Human Intestinal Organoid Model of Crohn's Disease.
    J Crohns Colitis. 2024 Aug 30:jjae139. doi: 10.1093.
    >> Share

  301. ROTH D, Dull MM, Horst LJ, Lindemann A, et al
    Integrin alphaVss6 - autoantigen and driver of epithelial remodeling in colon and bile ducts in primary sclerosing cholangitis and inflammatory bowel disease.
    J Crohns Colitis. 2024 Aug 30:jjae131. doi: 10.1093.
    >> Share

  302. TEMIDO MJ, Honap S, Danese S, Jairath V, et al
    Nested Randomized Controlled Trials in Large Databases: An Opportunity for Inflammatory Bowel Disease?
    J Crohns Colitis. 2024 Aug 29:jjae136. doi: 10.1093.
    >> Share

  303. NARDONE OM, Calabrese G, Bertin L, Ford AC, et al
    Prevalence of Sexual Dysfunction In Inflammatory Bowel Disease: Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2024 Aug 26:jjae133. doi: 10.1093.
    >> Share

  304. YERUSHALMY-FELER A, Lujan R, Loewenberg Weisband Y, Greenfeld S, et al
    Peripheral Blood Eosinophilia at Diagnosis of Inflammatory Bowel Disease Is Associated with Severe Disease Course; A Nationwide Study From the epi-IIRN Cohort.
    J Crohns Colitis. 2024 Aug 23:jjae130. doi: 10.1093.
    >> Share

  305. SIEGEL CA, Melmed GY
    Measurement Is Necessary But Not Sufficient to Improve Quality of Care for Patients With Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Aug 23:jjae119. doi: 10.1093.
    >> Share

  306. IBORRA M, Caballol B, Garrido A, Huguet JM, et al
    Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
    J Crohns Colitis. 2024 Aug 22:jjae127. doi: 10.1093.
    >> Share

  307. REPPELL M, Zheng X, Dreher I, Blaes J, et al
    HLA-DQA1*05 associates with anti-TNF immunogenicity and low adalimumab trough concentrations in inflammatory bowel disease patients from the SERENE UC and CD studies.
    J Crohns Colitis. 2024 Aug 20:jjae129. doi: 10.1093.
    >> Share

  308. HODGES P, Adeniyi O, Devani S, Nwoko C, et al
    Emerging patterns of inflammatory bowel disease in sub-Saharan Africa: 175 cases from an IBD network.
    J Crohns Colitis. 2024 Aug 14:jjae126. doi: 10.1093.
    >> Share

  309. VERSTOCKT B
    Epigenetic Fingerprints in IBD: From Methylation Patterns to Clinical Implications.
    J Crohns Colitis. 2024;18:1175-1176.
    >> Share

  310. PEYRIN-BIROULET L, Dubinsky MC, Sands BE, Panes J, et al
    Efficacy and Safety of Etrasimod in Patients with Moderately to Severely Active Isolated Proctitis: Results From the Phase 3 ELEVATE UC Clinical Programme.
    J Crohns Colitis. 2024;18:1270-1282.
    >> Share

  311. TANWAR H, Gnanasekaran JM, Allison D, Chuang LS, et al
    Unravelling the Oral-Gut Axis: Interconnection Between Periodontitis and Inflammatory Bowel Disease, Current Challenges, and Future Perspective.
    J Crohns Colitis. 2024;18:1319-1341.
    >> Share

  312. ATIA O, Bryder N, Mendelovici A, Ledderman N, et al
    The Epidemiology of Inflammatory Bowel Diseases During the COVID-19 Pandemic: Comparison of Two Nationwide Cohorts.
    J Crohns Colitis. 2024;18:1241-1249.
    >> Share

  313. FANTINI MC, Fiorino G, Colli A, Laharie D, et al
    Pragmatic Trial Design to Compare Real-world Effectiveness of Different Treatments for Inflammatory Bowel Diseases: The PRACTICE-IBD European Consensus.
    J Crohns Colitis. 2024;18:1222-1231.
    >> Share

  314. GELDOF J, Truyens M, Hanssens M, Van Gucht E, et al
    Prophylactic Versus Endoscopy-driven Treatment of Crohn's Postoperative Recurrence: A Retrospective, Multicentric, European Study [PORCSE Study].
    J Crohns Colitis. 2024;18:1202-1214.
    >> Share

  315. JANGI S, Zhao N, Hsia K, Park YS, et al
    Specific bacterial co-abundance groups are associated with inflammatory status in patients with ulcerative colitis.
    J Crohns Colitis. 2024 Aug 10:jjae125. doi: 10.1093.
    >> Share

  316. BRODERSEN JB, Kjeldsen J, Juel MA, Knudsen T, et al
    Changes in endoscopic activity and classification of lesions with panenteric capsule endoscopy in patients treated for Crohn's disease - a prospective blinded comparison with ileocolonoscopy, faecal calprotectin and C-reactive protein.
    J Crohns Colitis. 2024 Aug 10:jjae124. doi: 10.1093.
    >> Share

  317. DRAGONI G, Ke BJ, Picariello L, Abdurahiman S, et al
    The Impact of PAD4-dependent Neutrophil Extracellular Trap Formation on the Early Development of Intestinal Fibrosis in Crohn's Disease.
    J Crohns Colitis. 2024 Aug 10:jjae121. doi: 10.1093.
    >> Share

  318. UKASHI O, Kopylov U, Ungar B, Talan Asher A, et al
    Fecal calprotectin diagnostic level gradient along the small bowel in patients with Crohn's disease.
    J Crohns Colitis. 2024 Aug 9:jjae123. doi: 10.1093.
    >> Share

  319. DURICOVA D, Kucharzik T, Mitrova K, Maaser C, et al
    Intestinal Ultrasound-Ready to Use for Early Prediction of Disease Course in IBD?
    J Crohns Colitis. 2024;18:983-984.
    >> Share


  320. Corrigendum to: P032 Exploring the genetic sequence of action across the natural history of IBD.
    J Crohns Colitis. 2024;18:1173.
    >> Share

  321. SCHRAMM S, Liu LJ, Saad M, Dietz L, et al
    Blocking GPR15 Counteracts Integrin-dependent T Cell Gut Homing in Vivo.
    J Crohns Colitis. 2024;18:1162-1172.
    >> Share

    July 2024
  322. MUKHERJEE PK, Chauhan G, Komoroski J, Rieder F, et al
    Deciphering the Differences Between Stricturing With or Without Penetrating Crohn's Disease: One Step Closer to Solving the Puzzle.
    J Crohns Colitis. 2024 Jul 29:jjae099. doi: 10.1093.
    >> Share

  323. RAINE T, Myrelid P, Gordon H, Adamina M, et al
    ECCO Crohn's Disease Guidelines-A Personal View of the Journey from Questions to Recommendations.
    J Crohns Colitis. 2024 Jul 27:jjae107. doi: 10.1093.
    >> Share

  324. OYAMA H, Moroi R, Sakuma A, Shimoyama Y, et al
    Chronic poor sleep is associated with increased disease activity in patients with ulcerative colitis: Prospective observational study in Japan.
    J Crohns Colitis. 2024 Jul 25:jjae116. doi: 10.1093.
    >> Share

  325. DE CRISTOFARO E, Marafini I, Mancone R, Fiorillo M, et al
    Preventable predictive factors of post-colonoscopy colorectal cancer in inflammatory bowel disease.
    J Crohns Colitis. 2024 Jul 24:jjae115. doi: 10.1093.
    >> Share

  326. WU TH, Brandt CF, Scheike T, Burisch J, et al
    The Natural History of Crohn's Disease Leading to Intestinal Failure: A Longitudinal Cohort Study from 1973 to 2018.
    J Crohns Colitis. 2024 Jul 23:jjae114. doi: 10.1093.
    >> Share

  327. MA C, Feagan BG, Wang Z, Zou G, et al
    Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY Trial.
    J Crohns Colitis. 2024 Jul 20:jjae113. doi: 10.1093.
    >> Share

  328. INCIURAITE R, Ramonaite R, Kupcinskas J, Dalgediene I, et al
    The microRNA expression in crypt-top and crypt-bottom colonic epithelial cell populations demonstrates cell-type specificity and correlates with endoscopic activity in ulcerative colitis.
    J Crohns Colitis. 2024 Jul 18:jjae108. doi: 10.1093.
    >> Share

  329. LEIBOVITZH H, Nayeri S, Borowski K, Hernandez-Rocha C, et al
    Inflammatory bowel disease associated with primary sclerosing cholangitis is associated with an altered gut microbiome and bile acid profile.
    J Crohns Colitis. 2024 Jul 9:jjae096. doi: 10.1093.
    >> Share

  330. DE FRANCISCO R, Perez-Martinez I, Castano-Garcia A, Carballo-Folgoso L, et al
    Do patients with inflammatory bowel disease really know what other immune-mediated inflammatory diseases they are diagnosed with?
    J Crohns Colitis. 2024 Jul 9:jjae109. doi: 10.1093.
    >> Share

  331. HUANG CW, Yen HH, Chen YY
    Rescue Therapies for Steroid-Refractory Acute Severe Ulcerative Colitis: A Systemic Review and Network Meta-analysis.
    J Crohns Colitis. 2024 Jul 9:jjae111. doi: 10.1093.
    >> Share

  332. SWAMINATHAN A, Borichevsky GM, Frampton C, Kettle AJ, et al
    Development and investigation of a non-invasive disease severity index for inflammatory bowel disease.
    J Crohns Colitis. 2024 Jul 2:jjae106. doi: 10.1093.
    >> Share

  333. MA C, Haritunians T, Gremida AK, Syal G, et al
    Ileal Paneth Cell Phenotype is a Cellular Biomarker for Pouch Complications in Ulcerative Colitis.
    J Crohns Colitis. 2024 Jul 2:jjae105. doi: 10.1093.
    >> Share

    June 2024
  334. ILVEMARK JFKF, Wilkens R, Thielsen P, Dige A, et al
    Early intestinal ultrasound in severe ulcerative colitis identifies patients at increased risk of 1-year treatment failure and colectomy.
    J Crohns Colitis. 2024 Jun 28:jjae101. doi: 10.1093.
    >> Share

  335. PRADO E, Law CCY, Rowan C, Osman A, et al
    Lemann Index for assessing bowel damage in Crohn's disease: a real world study.
    J Crohns Colitis. 2024 Jun 27:jjae102. doi: 10.1093.
    >> Share

  336. SIEGEL CA, Rai V, Outtier A, Vermeire S, et al
    Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials.
    J Crohns Colitis. 2024 Jun 22:jjae097. doi: 10.1093.
    >> Share

  337. PROSBERG MV, Halkjaer SI, Lo B, Bremerskov-Koser C, et al
    Probiotic Treatment of Ulcerative Colitis with Trichuris suis ova: A Randomized, Double-blinded, Placebo-controlled Clinical Trial (the PROCTO Trial).
    J Crohns Colitis. 2024 Jun 20:jjae095. doi: 10.1093.
    >> Share

  338. MUNDHRA SK, Madan D, Golla R, Sahu P, et al
    Intravenous albumin infusion does not augment the response rate to a combination of exclusive enteral nutrition and intravenous steroids in acute severe ulcerative colitis: a randomized controlled trial.
    J Crohns Colitis. 2024 Jun 17:jjae094. doi: 10.1093.
    >> Share

  339. KELM M, Wagner L, Widder A, Pistorius R, et al
    Perioperative Enhanced Recovery Concepts Significantly Improve Postoperative Outcome in Patients with Crohn;s Disease.
    J Crohns Colitis. 2024 Jun 15:jjae090. doi: 10.1093.
    >> Share

  340. ADAMINA M, Minozzi S, Warusavitarne J, Buskens C, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment.
    J Crohns Colitis. 2024 Jun 15:jjae089. doi: 10.1093.
    >> Share

  341. GORDON H, Minozzi S, Kopylov U, Verstockt B, et al
    ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.
    J Crohns Colitis. 2024 Jun 15:jjae091. doi: 10.1093.
    >> Share

  342. NARULA N, Hamam H, Liu J, Wong ECL, et al
    Adaptive steroid tapering impedes corticosteroid-free remissions compared to forced tapering in clinical trials of ulcerative colitis.
    J Crohns Colitis. 2024 Jun 13:jjae092. doi: 10.1093.
    >> Share

  343. DANESE S, Dignass A, Matsuoka K, Ferrante M, et al
    Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Program.
    J Crohns Colitis. 2024 Jun 13:jjae088. doi: 10.1093.
    >> Share

  344. SUAREZ RG, Guruprasad N, Tata G, Zhang Z, et al
    Serum Metabolites Relate to Mucosal and Transmural Inflammation in Pediatric Crohn Disease.
    J Crohns Colitis. 2024 Jun 6:jjae085. doi: 10.1093.
    >> Share

  345. TAMBURINI FB, Tripathi A, Gold MP, Yang JC, et al
    Gut microbial species and endotypes associate with remission in ulcerative colitis patients treated with anti-TNF or anti-integrin therapy.
    J Crohns Colitis. 2024 Jun 5:jjae084. doi: 10.1093.
    >> Share

  346. GHOSH S, Feagan BG, Parra RS, Lopes S, et al
    Impact of upadacitinib induction and maintenance therapy on health-related quality of life, fatigue, and work productivity in patients with moderately-to-severely active Crohn's disease.
    J Crohns Colitis. 2024 Jun 5:jjae083. doi: 10.1093.
    >> Share

  347. ZHU F, Chen X, Qiu X, Guo W, et al
    Seeing Beyond the Surface: Superior performance of Ultrasound elastography over Milan ultrasound criteria in distinguishing fibrosis of ulcerative colitis.
    J Crohns Colitis. 2024 Jun 3:jjae081. doi: 10.1093.
    >> Share

  348. OGATA N, Maeda Y, Misawa M, Takenaka K, et al
    Artificial intelligence-assisted video colonoscopy for disease monitoring of ulcerative colitis: A prospective study.
    J Crohns Colitis. 2024 Jun 3:jjae080. doi: 10.1093.
    >> Share

  349. REVES J, Torres J
    Real-world Positioning and Effectiveness of First- and Second-Line Biological Therapy in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18:787-789.
    >> Share

  350. HASHIMOTO H, Takagi T, Asaeda K, Yasuda T, et al
    D-alanine Inhibits Murine Intestinal Inflammation by Suppressing IL-12 and IL-23 Production in Macrophages.
    J Crohns Colitis. 2024;18:908-919.
    >> Share

    May 2024
  351. WETWITTAYAKHLANG P, Lakatos PL
    Unravelling the Smoke Trail: Maternal Smoking, Childhood Exposure, and their Impact on Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18:659-660.
    >> Share

  352. ZAMAN S, Mohamedahmed AYY, Yassin NA
    Letter to the Editor - Minimally invasive surgery for Inflammatory Bowel Disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques.
    J Crohns Colitis. 2024 May 23:jjae065. doi: 10.1093.
    >> Share

  353. RIMOLA J, Castro-Poceiro J, Sapena V, Aduna M, et al
    MRI features indicative of permanent colon damage in ulcerative colitis: an exploratory study.
    J Crohns Colitis. 2024 May 20:jjae075. doi: 10.1093.
    >> Share

  354. CHIRRA P, Sleiman J, Gandhi NS, Gordon IO, et al
    Radiomics to Detect Inflammation and Fibrosis on Magnetic Resonance Enterography in Stricturing Crohn's Disease.
    J Crohns Colitis. 2024 May 18:jjae073. doi: 10.1093.
    >> Share

  355. GIORDANO A, Rovira M, Veny M, Barastegui R, et al
    Cyclophosphamide-free mobilisation increases safety while preserving the efficacy of autologous haematopoietic stem cell transplantation in refractory Crohn's disease patients.
    J Crohns Colitis. 2024 May 17:jjae076. doi: 10.1093.
    >> Share

  356. THOMANN AK, Schmitgen MM, Stephan JC, Ebert MP, et al
    Associations between brain morphology, inflammatory markers and symptoms of fatigue, depression or anxiety in active and remitted Crohn's disease.
    J Crohns Colitis. 2024 May 17:jjae078. doi: 10.1093.
    >> Share

  357. KELLERMANN L, Hansen SL, Maciag G, Granau AM, et al
    Influence of vitamin D receptor signaling and vitamin D on colonic epithelial cell fate decisions in ulcerative colitis.
    J Crohns Colitis. 2024 May 15:jjae074. doi: 10.1093.
    >> Share

  358. MONFORT-FERRE D, Boronat-Toscano A, Sanchez-Herrero JF, Caro A, et al
    Genome-wide DNA methylome and transcriptome profiling reveals key genes involved in the dysregulation of adipose-stem cells in Crohn's disease.
    J Crohns Colitis. 2024 May 15:jjae072. doi: 10.1093.
    >> Share

  359. FUMERY M, Serrero M, Bouguen G, Amiot A, et al
    Real-world comparison of the effectiveness between ustekinumab and vedolizumab in patients with ulcerative colitis exposed to at least one anti-TNF agent.
    J Crohns Colitis. 2024 May 14:jjae063. doi: 10.1093.
    >> Share

  360. POULSEN A, Rasmussen J, Wewer MD, Holm Hansen E, et al
    Re-resection Rates and Disease Recurrence in Crohn's Disease - A Population-Based Study Using Individual-Level Patient Data.
    J Crohns Colitis. 2024 May 10:jjae070. doi: 10.1093.
    >> Share

  361. UKASHI O, Lahat A, Ungar B, Levy H, et al
    Pan-enteric Crohn's capsule (Eliakim) score reliability and responsiveness to change in active Crohn's disease.
    J Crohns Colitis. 2024 May 9:jjae068. doi: 10.1093.
    >> Share

  362. LEIBOVITZH H, Sarbagili Shabat C, Hirsch A, Zittan E, et al
    Fecal transplantation for ulcerative colitis from diet conditioned donors followed by dietary intervention results in favorable gut microbial profile compared to fecal transplantation alone.
    J Crohns Colitis. 2024 May 9:jjae062. doi: 10.1093.
    >> Share

  363. MUNIZ PEDROGO DA, Sears CL, Melia JMP
    Colorectal cancer in inflammatory bowel disease: a review of the role of gut microbiota and bacterial biofilms in disease pathogenesis.
    J Crohns Colitis. 2024 May 4:jjae061. doi: 10.1093.
    >> Share

  364. TAVARES DE SOUSA H, Ferreira M, Gullo I, Rocha AM, et al
    Fibrosis-related transcriptome unveils a distinctive remodeling matrix pattern in penetrating ileal Crohn's disease.
    J Crohns Colitis. 2024 May 3:jjae064. doi: 10.1093.
    >> Share

  365. REGUEIRO M, Siegmund B, Yarur AJ, Steinwurz F, et al
    Etrasimod for the Treatment of Ulcerative Colitis: Analysis of Infection Events From the ELEVATE UC Clinical Program.
    J Crohns Colitis. 2024 May 3:jjae060. doi: 10.1093.
    >> Share

    April 2024
  366. CHETWOOD JD, Tran Y, Subramanian S, Smith PJ, et al
    Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2024 Apr 24:jjae059. doi: 10.1093.
    >> Share

  367. VIEUJEAN S, Lindsay JO, D'Amico F, Ahuja V, et al
    Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD.
    J Crohns Colitis. 2024;18:548-559.
    >> Share

  368. HINDMARCH DC, Malashanka S, Shows DM, Clarke AS, et al
    Janus Kinase Inhibitors Differentially Inhibit Specific Cytokine Signals in the Mesenteric Lymph Node Cells of Inflammatory Bowel Disease Patients.
    J Crohns Colitis. 2024;18:628-637.
    >> Share

  369. OLLECH JE, Yanai H
    Navigating Postoperative Management in Crohn's Disease: Insights from the PORCSE Study.
    J Crohns Colitis. 2024 Apr 20:jjae054. doi: 10.1093.
    >> Share

  370. SCHROEDER MK, Abushamma S, George AT, Ravella B, et al
    TOpCLASS Expert Consensus Classification of Perianal Fistulizing Crohn's Disease: A Real-World Application in a Serial Fistula MRI Cohort.
    J Crohns Colitis. 2024 Apr 20:jjae056. doi: 10.1093.
    >> Share

  371. BURTON-MURRAY H, Kiser K, Gurung J, Williams K, et al
    Avoidant/restrictive food intake disorder symptoms are not as frequent as other eating disorder symptoms when ulcerative colitis is in remission.
    J Crohns Colitis. 2024 Apr 18:jjae052. doi: 10.1093.
    >> Share

  372. BROWN M, Dodd A, Shi F, Greenwood E, et al
    Concordant B and T Cell Heterogeneity Inferred from the Multiomic Landscape of Peripheral Blood Mononuclear Cells in a Crohn's Disease Cohort.
    J Crohns Colitis. 2024 Apr 13:jjae055. doi: 10.1093.
    >> Share

  373. PETIT P, Leroyer A, Chamot S, Fumery M, et al
    Farming activities and risk of inflammatory bowel disease: a French nationwide population-based cohort study.
    J Crohns Colitis. 2024 Apr 12:jjae050. doi: 10.1093.
    >> Share

  374. MOHAMEDRASHED M, Garg M, Bohra A
    Advocating for Consensus: The crucial role of standardised Magnetic resonance imaging (MRE) protocols and image quality metrics in assessment of Crohn's disease.
    J Crohns Colitis. 2024 Apr 12:jjae051. doi: 10.1093.
    >> Share

  375. TIONG HT, Fan D, Frampton C, Ananthakrishnan AN, et al
    Physical Activity Is Associated With A Decreased Risk Of Developing Inflammatory Bowel Disease: A Systematic Review And Meta-Analysis.
    J Crohns Colitis. 2024 Apr 10:jjae053. doi: 10.1093.
    >> Share

  376. ZADORA W, Innocenti T, Verstockt B, Meijers B, et al
    Chronic kidney disease in inflammatory bowel disease, a systematic review and meta-analysis.
    J Crohns Colitis. 2024 Apr 8:jjae049. doi: 10.1093.
    >> Share

  377. MERTZ NORGARD B, Garvik OS, Zegers FD, Nielsen J, et al
    New surgery and hospital-diagnosed infections in elderly patients with inflammatory bowel disease undergoing surgery - a nationwide cohort study.
    J Crohns Colitis. 2024 Apr 5:jjae047. doi: 10.1093.
    >> Share

  378. VAN LINGEN E, Nooij S, Terveer E, Crossette E, et al
    Fecal Microbiota Transplantation engraftment after budesonide or placebo in patients with active ulcerative colitis using pre-selected donors: a randomized pilot study.
    J Crohns Colitis. 2024 Apr 4:jjae043. doi: 10.1093.
    >> Share

    March 2024
  379. KUMAR S, De Kock I, Blad W, Hare R, et al
    Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn's disease.
    J Crohns Colitis. 2024 Mar 30:jjae042. doi: 10.1093.
    >> Share

  380. VAN DEN HOUTE M, Guadagnoli L, Ohman L, Bergstedt A, et al
    Predictors of symptom trajectory in newly diagnosed ulcerative colitis: a 3-year follow-up cohort study.
    J Crohns Colitis. 2024 Mar 29:jjae046. doi: 10.1093.
    >> Share

  381. CUNHA MF, Roseira J
    Letter to the Editor regarding the article Minimally invasive surgery for Inflammatory Bowel Disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques.
    J Crohns Colitis. 2024 Mar 28:jjae045. doi: 10.1093.
    >> Share

  382. SCIBERRAS M, Farrugia Y, Gordon H, Furfaro F, et al
    Accuracy of Information given by ChatGPT for patients with Inflammatory Bowel Disease in relation to ECCO Guidelines.
    J Crohns Colitis. 2024 Mar 23:jjae040. doi: 10.1093.
    >> Share

  383. SHRESTHA S, Brand JS, Osooli M, Eriksson C, et al
    Spondyloarthritis in first-degree relatives and spouses of patients with inflammatory bowel disease: A nationwide population-based cohort study from Sweden.
    J Crohns Colitis. 2024 Mar 22:jjae041. doi: 10.1093.
    >> Share


  384. Corrigendum to: Influence of Early Life Factors, including breast milk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Mar 20:jjae021. doi: 10.1093.
    >> Share

  385. VAN GENNEP S, Fung ICN, de Jong DC, Ramkisoen RK, et al
    Histological Outcomes And Jak-Stat Signalling In Ulcerative Colitis Patients Treated With Tofacitinib.
    J Crohns Colitis. 2024 Mar 20:jjae031. doi: 10.1093.
    >> Share

  386. CON D, Hilley P, Chin S, Corte C, et al
    Safety and effectiveness of Janus kinase inhibitors in the management of inflammatory bowel disease following liver transplantation.
    J Crohns Colitis. 2024 Mar 19:jjae039. doi: 10.1093.
    >> Share

  387. FUNG M, Farbod Y, Kankouni H, Singh S, et al
    Does combined medical and surgical treatment improve perianal fistula outcomes in patients with Crohn's disease? A systematic review and meta-analysis.
    J Crohns Colitis. 2024 Mar 16:jjae035. doi: 10.1093.
    >> Share

  388. GENG Z, Li J, Zuo L, Zhang X, et al
    Intestinal adipocytes transdifferentiate into myofibroblast-like cells and contribute to fibrosis in Crohn's disease.
    J Crohns Colitis. 2024 Mar 11:jjae036. doi: 10.1093.
    >> Share

  389. ZAMAN S, Mohamedahmed AYY, Abdelrahman W, Abdalla HE, et al
    Minimally invasive surgery for Inflammatory Bowel Disease: a systematic review and meta-analysis of robotic versus laparoscopic surgical techniques.
    J Crohns Colitis. 2024 Mar 11:jjae037. doi: 10.1093.
    >> Share

  390. LEHMANN M, Weixler B, Elezkurtaj S, Loddenkemper C, et al
    Spatial single cell profiling using imaging mass cytometry - inflammatory versus penetrating Crohn's disease.
    J Crohns Colitis. 2024 Mar 11:jjae033. doi: 10.1093.
    >> Share

  391. ELLRICHMANN M, Schulte B, Conrad CC, Schoch S, et al
    Contrast enhanced endoscopic ultrasound detects early therapy response following anti-TNF-therapy in patients with ulcerative colitis.
    J Crohns Colitis. 2024 Mar 8:jjae034. doi: 10.1093.
    >> Share

  392. TEUGELS A, van den Eijnden I, Keersmaekers B, Verstockt B, et al
    Disease acceptance, but not perceived control, is uniquely associated with inflammatory bowel disease-related disability.
    J Crohns Colitis. 2024 Mar 6:jjae025. doi: 10.1093.
    >> Share

  393. BIEL C, Faber KN, Bank RA, Olinga P, et al
    Matrix metalloproteinases in intestinal fibrosis.
    J Crohns Colitis. 2024;18:462-478.
    >> Share

  394. WARSOP ZI, Manzo CA, Yu N, Yusuf B, et al
    Patient-reported Outcome Measures in Ileoanal Pouch Surgery: a Systematic Review.
    J Crohns Colitis. 2024;18:479-487.
    >> Share

  395. JOJART B, Resal T, Kata D, Molnar T, et al
    Plasminogen Activator Inhibitor 1 Is a Novel Faecal Biomarker for Monitoring Disease Activity and Therapeutic Response in Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18:392-405.
    >> Share

  396. WEBER S, Sitte S, Voegele AL, Sologub L, et al
    NLRP3 Inhibition Leads to Impaired Mucosal Fibroblast Function in Patients with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2024;18:446-461.
    >> Share

    February 2024
  397. ROSH JR, Turner D, Hyams JS, Dubinsky M, et al
    Outcomes in Adult Inflammatory Bowel Disease Clinical Trials: Assessment of Similarity Among Participants with Adolescent-Onset and Adult-Onset Disease.
    J Crohns Colitis. 2024 Feb 26:jjae030. doi: 10.1093.
    >> Share

  398. TORRES J, Colombel JF, Mary JY
    Lemman Index in Children: Still an Open Question.
    J Crohns Colitis. 2024;18:331-332.
    >> Share

  399. GEBEYEHU GG, Taylor F, Dobson L, Cummings JRF, et al
    Validation of the IBD-Control Questionnaire across different sociodemographic and clinical subgroups: secondary analysis of a nationwide electronic survey.
    J Crohns Colitis. 2024;18:275-285.
    >> Share

  400. GRANT RK, Jones GR, Plevris N, Lynch RW, et al
    Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset.
    J Crohns Colitis. 2024;18:286-290.
    >> Share

  401. DHALIWAL J, Tertigas D, Carman N, Lawrence S, et al
    Outcomes Following Acute Severe Colitis at Initial Presentation: A Multi-centre, Prospective, Paediatric Cohort Study.
    J Crohns Colitis. 2024;18:233-245.
    >> Share

  402. LO B, Biederman L, Rogler G, Dora B, et al
    Specific antibiotics increases the risk of flare-ups in patients with inflammatory bowel disease - results from a Danish nationwide population-based nested case-control study.
    J Crohns Colitis. 2024 Feb 17:jjae027. doi: 10.1093.
    >> Share

  403. ARJOMAND FARD N, Wine E
    Clostridium perfringens: A Potential Pathobiont in Inflammatory Bowel Disease.
    J Crohns Colitis. 2024 Feb 16:jjae019. doi: 10.1093.
    >> Share

  404. KOELINK PJ, Gomez-Mellado VE, Duijst S, van Roest M, et al
    The phospholipid flippase ATP8B1 is involved in the pathogenesis of Ulcerative Colitis via establishment of intestinal barrier function.
    J Crohns Colitis. 2024 Feb 16:jjae024. doi: 10.1093.
    >> Share

  405. REINISCH W, Colombel JF, D'Haens GR, Rimola J, et al
    Efficacy and Safety of Filgotinib for the Treatment of Perianal Fistulizing Crohn's Disease [DIVERGENCE 2]: a Phase 2, Randomized, Placebo-Controlled Trial.
    J Crohns Colitis. 2024 Feb 16:jjae003. doi: 10.1093.
    >> Share

  406. PRENTICE R, Flanagan E, Wright E, Prideaux L, et al
    Thiopurine metabolite shunting in late pregnancy increases the risk of intrahepatic cholestasis of pregnancy in women with inflammatory bowel disease, and can be managed with split-dosing.
    J Crohns Colitis. 2024 Feb 15:jjae023. doi: 10.1093.
    >> Share

  407. VLADIMIROVA N, Terslev L, Attauabi M, Madsen G, et al
    Peripheral joint and enthesis involvement in patients with newly diagnosed inflammatory bowel disease: symptoms, clinical and ultrasound findings - a population-based cohort study.
    J Crohns Colitis. 2024 Feb 15:jjae022. doi: 10.1093.
    >> Share

  408. SIGVARDSSON I, Ludvigsson J, Andersson B, Stordal K, et al
    Tobacco smoke exposure in early childhood and later risk of inflammatory bowel disease: A Scandinavian birth cohort study.
    J Crohns Colitis. 2024 Feb 8:jjae020. doi: 10.1093.
    >> Share

  409. GHOSH S, Feagan BG, Ott E, Gasink C, et al
    Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn's Disease and 4 Years in Ulcerative Colitis.
    J Crohns Colitis. 2024 Feb 4:jjae013. doi: 10.1093.
    >> Share

    January 2024
  410. KUO J, Uzunovic J, Jacobson A, Dourado M, et al
    Toxigenic Clostridium perfringens isolated from at-risk pediatric inflammatory bowel disease patients.
    J Crohns Colitis. 2024 Jan 24:jjae016. doi: 10.1093.
    >> Share

  411. DUAN M, Lu M, Diao Y, Cao L, et al
    Azathioprine plus exclusive enteral nutrition versus azathioprine monotherapy for the prevention of postoperative recurrence in patients with Crohn's disease: an open-label, single-centre, randomised controlled trial.
    J Crohns Colitis. 2024 Jan 22:jjae015. doi: 10.1093.
    >> Share

  412. YARUR AJ, Chiorean MV, Panes J, Jairath V, et al
    Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
    J Crohns Colitis. 2024 Jan 20:jjae007. doi: 10.1093.
    >> Share

  413. MAGRO F, Fernandes S, Patita M, Arroja B, et al
    The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients.
    J Crohns Colitis. 2024 Jan 19:jjae014. doi: 10.1093.
    >> Share


  414. Erratum to: Ustekinumab as Induction and Maintenance Therapy in Patients with Inflammatory Bowel Disease and Type II Autoimmune Pancreatitis: Report of Two Cases.
    J Crohns Colitis. 2024 Jan 19:jjae005. doi: 10.1093.
    >> Share

  415. BITTERLIN T, Valibouze C, Lenne X, Bruandet A, et al
    Hospital surgical volume-outcome relationship of postoperative morbidity for ileocolic resection in Crohn's disease: A French nationwide study of 4,205 patients.
    J Crohns Colitis. 2024 Jan 18:jjae010. doi: 10.1093.
    >> Share

  416. CHULKINA M, Rohmer C, McAninch S, Panganiban RP, et al
    Increased activity of MAPKAPK2 within mesenchymal cells as a target for inflammation associated fibrosis in Crohn's Disease.
    J Crohns Colitis. 2024 Jan 15:jjae009. doi: 10.1093.
    >> Share

  417. DESAI A, Hashash JG, Kochhar GS, Hayney MS, et al
    Recombinant Zoster Vaccine (RZV) is Effective in Patients with Inflammatory Bowel Disease: A US Propensity Matched Cohort Study.
    J Crohns Colitis. 2024 Jan 15:jjae008. doi: 10.1093.
    >> Share

  418. RODRIGUEZ-ALCOLADO L, Grueso-Navarro E, Arias A, Lucendo AJ, et al
    Impact of HLA-DQA1 *05 Genotype in Immunogenicity and Failure to Treatment with Tumor Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2024 Jan 14:jjae006. doi: 10.1093.
    >> Share

  419. WONG C, van Oostrom J, Pittet V, Bossuyt P, et al
    Baseline Data and Measurement Instruments Reported In Observational Studies In Inflammatory Bowel Disease: Results From A Systematic Review.
    J Crohns Colitis. 2024 Jan 12:jjae004. doi: 10.1093.
    >> Share

  420. TIMAR AE, Parniczky A, Budai KA, Hernadfoi MV, et al
    Beyond the Gut: A Systematic Review and Meta-analysis of Advanced Therapies for Inflammatory Bowel Disease-associated Extraintestinal Manifestations.
    J Crohns Colitis. 2024 Jan 8:jjae002. doi: 10.1093.
    >> Share

  421. PRUIJT MJ, de Voogd FAE, Montazeri NSM, van Etten-Jamaludin FS, et al
    DIAGNOSTIC ACCURACY OF INTESTINAL ULTRASOUND IN THE DETECTION OF INTRA-ABDOMINAL COMPLICATIONS IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS.
    J Crohns Colitis. 2024 Jan 4:jjad215. doi: 10.1093.
    >> Share

    December 2023
  422. TAL N, Tzivinikos C, Gasparetto M, Serban DE, et al
    Clinical Features and Natural History of Paediatric Patients with Ulcerative Proctitis: A Multicentre Study from the Paediatric IBD Porto Group of ESPGHAN.
    J Crohns Colitis. 2023;17:1939-1948.
    >> Share

  423. HASSAN-ZAHRAEE M, Ye Z, Xi L, Dushin E, et al
    Baseline serum and stool microbiome biomarkers predict clinical efficacy and tissue molecular response after ritlecitinib induction therapy in ulcerative colitis.
    J Crohns Colitis. 2023 Dec 23:jjad213. doi: 10.1093.
    >> Share

  424. DOLINGER MT, Aronskyy I, Kellar A, Spencer E, et al
    Early Intestinal Ultrasound Response to Biologic Therapy Predicts Endoscopic Remission in Children with Ileal Crohn's Disease: Results from the Prospective Super Sonic Study.
    J Crohns Colitis. 2023 Dec 23:jjad216. doi: 10.1093.
    >> Share


  425. Correction to: Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Disease: A National Cohort Study from Sweden.
    J Crohns Colitis. 2023 Dec 23:jjad210. doi: 10.1093.
    >> Share

  426. VUYYURU SK, Solitano V, Singh S, Hanzel J, et al
    Scoring indices for perianal fistulizing Crohn's disease: A systematic review.
    J Crohns Colitis. 2023 Dec 21:jjad214. doi: 10.1093.
    >> Share

  427. HAMMOUDI N, Sachar D, D'Haens G, Reinisch W, et al
    Outcomes and endpoints of postoperative recurrence in Crohn's Disease: systematic review and consensus conference.
    J Crohns Colitis. 2023 Dec 19:jjad205. doi: 10.1093.
    >> Share

  428. NIEVA C, Pryor J, Williams GM, Hoedt EC, et al
    The Impact of Dietary Interventions on the Microbiota in Inflammatory Bowel Disease: A Systematic Review.
    J Crohns Colitis. 2023 Dec 15:jjad204. doi: 10.1093.
    >> Share

  429. VERMEIRE S, Danese S, Sandborn WJ, Schreiber S, et al
    Efficacy and Safety of the Anti-Mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.
    J Crohns Colitis. 2023 Dec 14:jjad199. doi: 10.1093.
    >> Share

  430. LEWIS A, Humphreys DT, Pan-Castillo B, Berti G, et al
    Epigenetic and metabolic reprogramming of fibroblasts in Crohn's disease strictures reveals histone deacetylases as therapeutic targets.
    J Crohns Colitis. 2023 Dec 9:jjad209. doi: 10.1093.
    >> Share

  431. COLOMBEL JF, Schreiber S, D'Haens G, Rizzo J, et al
    Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.
    J Crohns Colitis. 2023 Dec 9:jjad206. doi: 10.1093.
    >> Share

  432. GROS B, Goodall M, Plevris N, Constantine-Cooke N, et al
    Real-World Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis.
    J Crohns Colitis. 2023 Dec 8:jjad187. doi: 10.1093.
    >> Share

  433. KAPIZIONI C, Desoki R, Lam D, Balendran K, et al
    Biologic therapy for inflammatory bowel disease: Real-world comparative effectiveness and impact of drug sequencing in 13,222 patients within the UK IBD BioResource.
    J Crohns Colitis. 2023 Dec 2:jjad203. doi: 10.1093.
    >> Share

  434. VAN DER DOES DE WILLEBOIS EML, Sari C, Mookhoek A, Joustra V, et al
    The clinical relevance of an inflamed appendix in Crohn's disease.
    J Crohns Colitis. 2023 Dec 1:jjad202. doi: 10.1093.
    >> Share

  435. HU L, Wu S, Shu Y, Su K, et al
    Impact of Maternal Smoking, Offspring Smoking, and Genetic Susceptibility on Crohn's Disease and Ulcerative Colitis.
    J Crohns Colitis. 2023 Dec 1:jjad200. doi: 10.1093.
    >> Share

    November 2023
  436. WATANABE K, Peyrin-Biroulet L, Danese S, Fujitani Y, et al
    Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post hoc Analysis of the Phase 2b/3 SELECTION Study.
    J Crohns Colitis. 2023 Nov 29:jjad201. doi: 10.1093.
    >> Share

  437. KLOMBERG RCW, van der Wal HC, Aardoom MA, Kemos P, et al
    Improved clinical outcomes with early anti-tumour necrosis factor alpha therapy in children with newly diagnosed Crohn's disease: real world data from the international prospective PIBD-SETQuality inception cohort study.
    J Crohns Colitis. 2023 Nov 27:jjad197. doi: 10.1093.
    >> Share

  438. SCHELLENBERG C, Lagrange J, Ahmed MU, Arnone D, et al
    The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease.
    J Crohns Colitis. 2023 Nov 27:jjad198. doi: 10.1093.
    >> Share

  439. WANG Y, He Q, Yao D, Huang Y, et al
    Histologic image-based ensemble model to identify myenteric plexitis and predict endoscopic postoperative recurrence in Crohn's disease: a multicentre, retrospective study.
    J Crohns Colitis. 2023 Nov 24:jjad196. doi: 10.1093.
    >> Share

  440. BISHU S
    Nurturing the Gut, Moms with IBD and Their Babies.
    J Crohns Colitis. 2023;17:1705-1706.
    >> Share

  441. DORK R, Pelczar P, Shiri AM, Volmari A, et al
    Myeloid Cell-Specific Deletion of PDGFR-alpha Promotes Dysbiotic Intestinal Microbiota and thus Increased Colitis Susceptibility.
    J Crohns Colitis. 2023;17:1858-1869.
    >> Share

  442. PUGLIESE N, Dal Buono A, Armuzzi A
    Unveiling the Complexity of Porto-Sinusoidal Vascular Disorder in Inflammatory Bowel Disease: A Call for Further Investigation.
    J Crohns Colitis. 2023;17:1892.
    >> Share

  443. REVES J, Mascarenhas A, Jose Temido M, Morao B, et al
    Early intervention with biologic therapy in Crohn s disease: how early is early?
    J Crohns Colitis. 2023;17:1752-1760.
    >> Share

  444. SCHULZE LL, Becker E, Dedden M, Liu LJ, et al
    Differential Effects of Ontamalimab Versus Vedolizumab on Immune Cell Trafficking in Intestinal Inflammation and Inflammatory Bowel Disease.
    J Crohns Colitis. 2023;17:1817-1832.
    >> Share

  445. MEHTA S
    Intestinal Failure: A Small but Imperfectly Phenotyped Complication of Crohn's Disease.
    J Crohns Colitis. 2023 Nov 21:jjad154. doi: 10.1093.
    >> Share

  446. ROCHA CH, Walshe M, Birch S, Sabic K, et al
    Clinical predictors of early and late endoscopic recurrence following ileocolonic resection in Crohn's disease.
    J Crohns Colitis. 2023 Nov 17:jjad186. doi: 10.1093.
    >> Share

  447. RONSIN C, Le Berre C, Ville S
    Kidney injuries as Extra Intestinal Manifestation of Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Nov 15:jjad191. doi: 10.1093.
    >> Share

  448. VERSTOCKT B, Vermeire S, Peyrin-Biroulet L, Mosig R, et al
    The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study.
    J Crohns Colitis. 2023 Nov 11:jjad192. doi: 10.1093.
    >> Share

  449. SZEKELY H, Th LMT, Rancz A, Walter A, et al
    Anti-tumor necrosis factor alpha versus corticosteroids: a threefold difference in the occurence of venous thromboembolism in Inflammatory Bowel Disease - a systematic review and meta-analysis.
    J Crohns Colitis. 2023 Nov 11:jjad193. doi: 10.1093.
    >> Share

  450. TANDON P, Huang VW, Feig DS, Saskin R, et al
    Differences in Healthcare Utilization in Women with and without Inflammatory Bowel Diseases During Preconception, Pregnancy and Postpartum: A Population-Based Cohort Study.
    J Crohns Colitis. 2023;17:1587-1595.
    >> Share

  451. DRUVEFORS E, Myrelid P, Andersson RE, Landerholm K, et al
    Female and Male Fertility after Colectomy and Reconstructive Surgery in Inflammatory Bowel Diesase: A National Cohort Study from Sweden.
    J Crohns Colitis. 2023;17:1631-1638.
    >> Share

  452. RAINE T, Ishiguro Y, Rubin DT, Finney-Hayward T, et al
    Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: a Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
    J Crohns Colitis. 2023 Nov 6:jjad190. doi: 10.1093.
    >> Share

  453. LIU Z, Alexander JL, Eng KY, Ibraheim H, et al
    Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
    J Crohns Colitis. 2023 Nov 6:jjad182. doi: 10.1093.
    >> Share

  454. VERMEIRE S, Hanzel J, Lowenberg M, Ferrante M, et al
    Early versus Late Use of Vedolizumab in Ulcerative Colitis: Clinical, Endoscopic, and Histological Outcomes.
    J Crohns Colitis. 2023 Nov 2:jjad179. doi: 10.1093.
    >> Share

  455. ROBLIN X, Nancey S, Papamichael K, Duru G, et al
    Higher serum infliximab concentrations following subcutaneous dosing are associated with deep remission in patients with inflammatory bowel disease.
    J Crohns Colitis. 2023 Nov 2:jjad188. doi: 10.1093.
    >> Share

  456. VUYYURU SK, Solitano V, Narula N, Lee MJ, et al
    Pharmacological therapies for the management of fistulising Crohn's disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2023 Nov 2:jjad185. doi: 10.1093.
    >> Share

  457. GISBERT JP, Chaparro M
    De-escalation of biological treatment in inflammatory bowel disease: A comprehensive review.
    J Crohns Colitis. 2023 Nov 1:jjad181. doi: 10.1093.
    >> Share

  458. CASAS DEZA D, Polo Cuadro C, de Francisco R, Vela Gonzalez M, et al
    Initial management of intraabdominal abscesses and preventive strategies for abscess recurrence in penetrating Crohn's disease: a national multicenter study based on ENEIDA registry.
    J Crohns Colitis. 2023 Nov 1:jjad184. doi: 10.1093.
    >> Share

    October 2023
  459. BOYD T, Araka EB, Kochar B, Ananthakrishnan AN, et al
    Differences in Management and Outcomes of Older and Younger Adults with Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2023 Oct 28:jjad183. doi: 10.1093.
    >> Share

  460. COHEN NA, Weber CR, Cheng JX, Choi D, et al
    Ozanimod-Exposed Patients with Ulcerative Colitis Undergoing Total Colectomy Exhibit Unique Lymph Node Histologic Changes.
    J Crohns Colitis. 2023 Oct 25:jjad174. doi: 10.1093.
    >> Share

  461. ASSCHER VER, Rodriguez Girondo MDM, Fens J, Waars SN, et al
    Frailty screening associates with hospitalization and decline in quality of life and functional status in older patients with inflammatory bowel disease.
    J Crohns Colitis. 2023 Oct 23:jjad175. doi: 10.1093.
    >> Share

  462. JATKOWSKA A, White B, Nichols B, Svolos V, et al
    Development and Validation of the Glasgow Exclusive Enteral Nutrition Index of Compliance.
    J Crohns Colitis. 2023;17:1426-1435.
    >> Share

  463. AMIOT A, Chaibi S, Bouhnik Y, Serrero M, et al
    Prevalence and Determinants of Fatigue in Patients with IBD: A Cross-Sectional Survey from the GETAID.
    J Crohns Colitis. 2023;17:1418-1425.
    >> Share

  464. MULLER M, Broseus J, Guilloteau A, Wasse S, et al
    Lymphoma In Patients With Inflammatory Bowel Disease: A Multicenter Collaborative Study Between Getaid And Lysa.
    J Crohns Colitis. 2023 Oct 18:jjad177. doi: 10.1093.
    >> Share

  465. ALIBERT L, Betton L, Falcoz A, Manceau G, et al
    Does KONO-S anastomosis reduce recurrence in Crohn's disease compared to conventional ileocolonic anastomosis? A nationwide propensity score-matched study from GETAID Chirurgie Group (KoCoRICCO study).
    J Crohns Colitis. 2023 Oct 18:jjad176. doi: 10.1093.
    >> Share

  466. ROBLIN X, Paul S
    Adalimumab: A 'Maillon Faible' in the Treatment of Ulcerative Colitis?
    J Crohns Colitis. 2023 Oct 17:jjad167. doi: 10.1093.
    >> Share

  467. RYMARCZYK D, Schultz W, Borowa A, Friedman JR, et al
    Deep learning models capture histological disease activity in Crohn's Disease and Ulcerative Colitis with high fidelity.
    J Crohns Colitis. 2023 Oct 10:jjad171. doi: 10.1093.
    >> Share

  468. VERSTOCKT B, Pivorunas V, Mahi NA, Smaoui N, et al
    Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.
    J Crohns Colitis. 2023 Oct 6:jjad170. doi: 10.1093.
    >> Share

  469. FERRANTE M, Irving PM, Abreu MT, Axler J, et al
    Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.
    J Crohns Colitis. 2023 Oct 5:jjad168. doi: 10.1093.
    >> Share

    September 2023
  470. ATREYA R, Kuhbacher T, Waldner MJ, Hirschmann S, et al
    Submucosal injection of the RNA oligonucleotide GUT-1 in active ulcerative colitis patients: A randomized, double-blind, placebo-controlled phase 2a induction trial.
    J Crohns Colitis. 2023 Sep 30:jjad162. doi: 10.1093.
    >> Share

  471. BAI BYH, Reppell M, Smaoui N, Waring JF, et al
    Baseline expression of immune gene modules in blood is associated with primary response to anti-TNF therapy in Crohn's disease patients.
    J Crohns Colitis. 2023 Sep 30:jjad166. doi: 10.1093.
    >> Share

  472. BONAZ B, Sinniger V
    Targeting the Vagus Nerve to Treat Inflammatory Bowel Disease?
    J Crohns Colitis. 2023 Sep 21:jjad149. doi: 10.1093.
    >> Share

  473. D'HAENS G, Eberhardson M, Cabrijan Z, Danese S, et al
    Neuroimmune modulation through vagus nerve stimulation reduces inflammatory activity in Crohn's disease patients: a prospective open label study.
    J Crohns Colitis. 2023 Sep 21:jjad151. doi: 10.1093.
    >> Share

  474. FOCHT G, Turner D
    Lemman Index in pediatric Crohn's disease - evidence is accumulating.
    J Crohns Colitis. 2023 Sep 14:jjad161. doi: 10.1093.
    >> Share

  475. JEW M, Meserve J, Eisenstein S, Jairath V, et al
    Temporary Faecal Diversion for Refractory Perianal and/or Distal Colonic Crohn's Disease in the Biologic Era: An Updated Systematic Review with Meta-Analysis.
    J Crohns Colitis. 2023 Sep 14:jjad159. doi: 10.1093.
    >> Share

  476. VIOLA A, Li Voti R, Bivacqua C, de Francesco C, et al
    Mitigating the risk of Tofacitinib-induced adverse events in the elderly population with Ulcerative Colitis.
    J Crohns Colitis. 2023 Sep 13:jjad158. doi: 10.1093.
    >> Share

  477. BEHESHTI MAAL A, Shahrbaf MA, Sadri B, Hossein-Khannazer N, et al
    Prevalence of hepatobiliary manifestations in inflammatory bowel disease: a GRADE assessed systematic review and meta-analysis on more than 1.7 million patients.
    J Crohns Colitis. 2023 Sep 11:jjad157. doi: 10.1093.
    >> Share

  478. HARNIK S, Abitbol CM, Haj Natour O, Yavzori M, et al
    Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study.
    J Crohns Colitis. 2023 Sep 11:jjad156. doi: 10.1093.
    >> Share

  479. NIELSEN KR, Midjord J, Lophaven SN, Langholz E, et al
    The incidence and prevalence of inflammatory bowel disease continues to increase in the Faroe Islands - a cohort study from 1960-2020.
    J Crohns Colitis. 2023 Sep 5:jjad155. doi: 10.1093.
    >> Share

  480. SINGH A, Midha V, Kaur K, Mahajan R, et al
    Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective, open-label, randomized, pilot study.
    J Crohns Colitis. 2023 Sep 1:jjad153. doi: 10.1093.
    >> Share

    August 2023
  481. DANESE S, Panaccione R, Abreu MT, Rubin DT, et al
    Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension.
    J Crohns Colitis. 2023 Aug 31:jjad146. doi: 10.1093.
    >> Share

  482. TRINH S, Andrew B, Vasudevan A
    6-mercaptopurine in ulcerative colitis: the potential of upfront dosing with allopurinol.
    J Crohns Colitis. 2023 Aug 29:jjad150. doi: 10.1093.
    >> Share

  483. PIAZZA O SED N, Noviello D, Filippi E, Conforti F, et al
    Superior predictive value of transmural over endoscopic severity for colectomy risk in ulcerative colitis: a multicenter prospective cohort study.
    J Crohns Colitis. 2023 Aug 26:jjad152. doi: 10.1093.
    >> Share

  484. MILO F, Imondi C, D'Amore C, Angelino G, et al
    Short Term Psychodynamic Psychotherapy in addition to standard medical therapy increases clinical remission in Adolescents and Young Adults with Inflammatory Bowel Disease: a randomised controlled trial.
    J Crohns Colitis. 2023 Aug 24:jjad145. doi: 10.1093.
    >> Share

  485. REINISCH W, Pradhan V, Ahmad S, Zhang Z, et al
    Alternative endoscopy reading paradigms determine score reliability and effect size in ulcerative colitis.
    J Crohns Colitis. 2023 Aug 24:jjad134. doi: 10.1093.
    >> Share

  486. FEAKINS R, Borralho Nunes P, Driessen A, Gordon IO, et al
    Definitions of histological abnormalities in inflammatory bowel disease: an ECCO position paper.
    J Crohns Colitis. 2023 Aug 22:jjad142. doi: 10.1093.
    >> Share

  487. WEWER MD, Jansson S, Malham M, Burisch J, et al
    Disease Activity Patterns of Paediatric Inflammatory Bowel Disease - A Danish Nationwide Cohort Study (1996-2018).
    J Crohns Colitis. 2023 Aug 21:jjad144. doi: 10.1093.
    >> Share

  488. QIAN W, Xu Y, Wen W, Huang L, et al
    Exosomal miR-103a-3p from Crohn's Creeping Fat-Derived Adipose-Derived Stem Cells Contributes to Intestinal Fibrosis by Targeting TGFBR3 and Activating Fibroblasts.
    J Crohns Colitis. 2023;17:1291-1308.
    >> Share

  489. HU X, Jiao F, Deng J, Zhou Z, et al
    Intestinal Epithelial Cell-specific Deletion of Cytokine-inducible SH2-containing Protein Alleviates Experimental Colitis in Ageing Mice.
    J Crohns Colitis. 2023;17:1278-1290.
    >> Share

  490. GORDON H, Rodger B, Lindsay JO, Stagg AJ, et al
    Recruitment and Residence of Intestinal T Cells - Lessons for Therapy in Inflammatory Bowel Disease.
    J Crohns Colitis. 2023;17:1326-1341.
    >> Share

  491. WRIGHT EK, Chaparro M, Gionchetti P, Hamilton AL, et al
    Adalimumab Clearance, rather than Trough Level, May Have Greatest Relevance to Crohn's Disease Therapeutic Outcomes Assessed Clinically and Endoscopically.
    J Crohns Colitis. 2023 Aug 18:jjad140. doi: 10.1093.
    >> Share

  492. KIM K, Park S, Lee Y, Baek J, et al
    Transcriptomic Profiling and Cellular Composition of Creeping Fat in Crohn's disease.
    J Crohns Colitis. 2023 Aug 18:jjad141. doi: 10.1093.
    >> Share


  493. Corrigendum to: Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
    J Crohns Colitis. 2023 Aug 17:jjad136. doi: 10.1093.
    >> Share

  494. PELTON M, Ssentongo P, Sun A, Groff D, et al
    Race & Ethnic Representation in Crohn's Disease Trials of Biologic and Small Molecule Medications: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023 Aug 16:jjad138. doi: 10.1093.
    >> Share

  495. SCHREIBER S, Danese S, Dignass A, Domenech E, et al
    Defining Comprehensive Disease Control for use as a Treatment Target for Ulcerative Colitis in Clinical Practice: International Delphi Consensus Recommendations.
    J Crohns Colitis. 2023 Aug 16:jjad130. doi: 10.1093.
    >> Share

  496. RANJAN MK, Kumar P, Kumar Vuyyuru S, Kante B, et al
    Thiopurines have sustained long-term effectiveness in patients with inflammatory bowel disease which is independent of disease duration at initiation: A propensity score matched analysis.
    J Crohns Colitis. 2023 Aug 16:jjad135. doi: 10.1093.
    >> Share

  497. WIESE JJ, Manna S, Kuhl AA, Fasci A, et al
    Myenteric plexus immune cell infiltrations and neurotransmitter expression in Crohn's disease and ulcerative colitis.
    J Crohns Colitis. 2023 Aug 11:jjad122. doi: 10.1093.
    >> Share

  498. LIN S, Hannon E, Reppell M, Waring JF, et al
    Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease.
    J Crohns Colitis. 2023 Aug 8:jjad133. doi: 10.1093.
    >> Share

  499. VERMEIRE S, Feagan BG, Peyrin-Biroulet L, Oortwijn A, et al
    Withdrawal and Re-treatment with Filgotinib in Ulcerative Colitis: Post Hoc Analyses of the Phase 2b/3 SELECTION and SELECTIONLTE Studies.
    J Crohns Colitis. 2023 Aug 4:jjad123. doi: 10.1093.
    >> Share

  500. KRISHNAMOORTHY A, Chandrapalan S, Ahmed M, Arasaradnam RP, et al
    The Diagnostic Utility of Volatile Organic Compounds in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023 Aug 4:jjad132. doi: 10.1093.
    >> Share

  501. HURYCH J, Mascellani Bergo A, Lerchova T, Hlinakova L, et al
    Faecal bacteriome and metabolome profiles associated with decreased mucosal inflammatory activity upon anti-TNF therapy in paediatric Crohn's disease.
    J Crohns Colitis. 2023 Aug 1:jjad126. doi: 10.1093.
    >> Share

  502. BRODERSEN JB, Jensen MD, Leenhardt R, Kjeldsen J, et al
    Artificial intelligence-assisted analysis of pan-enteric capsule endoscopy in patients with suspected Crohn's disease. A study on diagnostic performance.
    J Crohns Colitis. 2023 Aug 1:jjad131. doi: 10.1093.
    >> Share

  503. JOUSTRA V, Li Yim AYF, van Gennep S, Hageman I, et al
    Peripheral blood DNA methylation signatures and response to tofacitinib in moderate-to-severe ulcerative colitis.
    J Crohns Colitis. 2023 Aug 1:jjad129. doi: 10.1093.
    >> Share

  504. GUADAGNOLI L, Horrigan J, Walentynowicz M, Salwen-Deremer JK, et al
    Sleep quality drives next day pain and fatigue in adults with inflammatory bowel disease: A short report.
    J Crohns Colitis. 2023 Aug 1:jjad128. doi: 10.1093.
    >> Share

    July 2023
  505. KIM K, Oh SJ, Lee J, Kwon A, et al
    Regulatory Variants on the Leukocyte Immunoglobulin-Like Receptor Gene Cluster are Associated with Crohn's Disease and Interact with Regulatory Variants for TAP2.
    J Crohns Colitis. 2023 Jul 31:jjad127. doi: 10.1093.
    >> Share

  506. CARON B, Jairath V, Laurent V, Stoker J, et al
    Defining magnetic resonance imaging treatment response and remission in Crohn's disease: a systematic review.
    J Crohns Colitis. 2023 Jul 31:jjad125. doi: 10.1093.
    >> Share

  507. GARCIA MJ, Rivero M, Fernandez-Clotet A, de Francisco R, et al
    Comparative Study Of The Effectiveness Of Vedolizumab Versus Ustekinumab After Anti-Tnf Failure In Crohn's Disease (Versus-Cd): Data From Eneida Registry.
    J Crohns Colitis. 2023 Jul 31:jjad124. doi: 10.1093.
    >> Share

  508. UNGARO RC, Kadali H, Zhang W, Adsul S, et al
    Impact of Concomitant 5-Aminosalicylic Acid Therapy on Vedolizumab Efficacy and Safety in Inflammatory Bowel Disease: Post Hoc Analyses of Clinical Trial Data.
    J Crohns Colitis. 2023 Jul 26:jjad113. doi: 10.1093.
    >> Share

  509. ATIA O, Friss C, Focht G, Magen Rimon R, et al
    Durability of the first biologic in patients with Crohn's disease: A nationwide study from the epi-IIRN.
    J Crohns Colitis. 2023 Jul 19:jjad121. doi: 10.1093.
    >> Share

  510. PARONI M, Leccese G, Ranzani V, Moschetti G, et al
    An intestinal Th17 subset is associated with inflammation in Crohn's Disease and activated by adherent-invasive Escherichia coli (AIEC).
    J Crohns Colitis. 2023 Jul 18:jjad119. doi: 10.1093.
    >> Share

  511. UEDA T, Koyama F, Sugita A, Ikeuchi H, et al
    Endoscopic lesions of postoperative anastomotic area in patients with Crohn's disease in the biologic era: A Japanese multi-center nationwide cohort study.
    J Crohns Colitis. 2023 Jul 14:jjad116. doi: 10.1093.
    >> Share

  512. HUININK STB, Thomassen D, Steyerberg EW, Pauwels RWM, et al
    Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 patients from 12 studies.
    J Crohns Colitis. 2023 Jul 12:jjad118. doi: 10.1093.
    >> Share

  513. SANDS BE, Schreiber S, Blumenstein I, Chiorean MV, et al
    Clinician's Guide to Using Ozanimod for the Treatment of Ulcerative Colitis.
    J Crohns Colitis. 2023 Jul 12:jjad112. doi: 10.1093.
    >> Share

  514. GONCZI L, Lakatos L, Golovics PA, Ilias A, et al
    Declining trends of reoperations and disease behavior progression in Crohn's disease over different therapeutic eras - a prospective population-based study from western Hungary between 1977-2020, data from the Veszprem cohort.
    J Crohns Colitis. 2023 Jul 9:jjad117. doi: 10.1093.
    >> Share

  515. GILMORE R, Tan L, Fernandes R, An YK, et al
    Upadacitinib Salvage Therapy for Infliximab experienced patients with Acute Severe Ulcerative Colitis.
    J Crohns Colitis. 2023 Jul 9:jjad115. doi: 10.1093.
    >> Share

  516. BRYANT RV, Travis SPL
    APOLLO Has Landed: PROMS and Histology in UC.
    J Crohns Colitis. 2023;17:1027-1028.
    >> Share

  517. UZZAN M, Bouhnik Y, Abreu M, Ahmad HA, et al
    Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions.
    J Crohns Colitis. 2023;17:1066-1078.
    >> Share

  518. LEDDER O, Turner D
    Multi-item Measures for Paediatric Inflammatory Bowel Diseases: The ABCs of All Those Acronyms.
    J Crohns Colitis. 2023;17:1154-1168.
    >> Share

  519. GRIMSDOTTIR S, Attauabi M, Kristine Dahl E, Burisch J, et al
    Systematic Review with Meta-analysis: The Impact of Cancer Treatments on the Disease Activity of Inflammatory Bowel Diseases.
    J Crohns Colitis. 2023;17:1139-1153.
    >> Share

  520. ALEXANDERSSON BT, Andreasson A, Hedin C, Broms G, et al
    Inflammatory bowel disease is not linked to a higher rate of adverse events in colonoscopy - a nationwide population-based study in Sweden.
    J Crohns Colitis. 2023 Jul 4:jjad114. doi: 10.1093.
    >> Share

  521. SCHREIBER S, Rubin DT, Ng SC, Peyrin-Biroulet L, et al
    Major Adverse Cardiovascular Events by Baseline Cardiovascular Risk in Patients with Ulcerative Colitis Treated with Tofacitinib: Data from the OCTAVE Clinical Programme.
    J Crohns Colitis. 2023 Jul 4:jjad104. doi: 10.1093.
    >> Share

    June 2023
  522. PARIGI TL, Cannatelli R, Nardone OM, Zammarchi I, et al
    Neutrophil-only histological assessment of ulcerative colitis correlates with endoscopic activity and predicts long-term outcomes in a multicenter study.
    J Crohns Colitis. 2023 Jun 30:jjad110. doi: 10.1093.
    >> Share

  523. SEETHARAMAN J, Srivastava A, Yadav RR, Singh SK, et al
    Visceral fat indices: Do they help differentiate Crohn's disease and Intestinal tuberculosis in children?
    J Crohns Colitis. 2023 Jun 30:jjad109. doi: 10.1093.
    >> Share

  524. GORDON H, Burisch J, Ellul P, Karmiris K, et al
    ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Jun 23:jjad108. doi: 10.1093.
    >> Share

  525. FENG R, Tian Z, Mao R, Ma R, et al
    Gut microbiome generated phenylacetylglutamine from dietary protein is associated with Crohn's Disease and exacerbates colitis in mouse model possibly via platelet activation.
    J Crohns Colitis. 2023 Jun 23:jjad098. doi: 10.1093.
    >> Share

  526. MATHEWS SN, Lukin DJ
    Shifting the Inflammatory Balance in Ulcerative Colitis Through Diet: A Mediterranean Diet Pattern is Associated with Improvements in Dysbiosis and Disease Activity.
    J Crohns Colitis. 2023 Jun 23:jjad095. doi: 10.1093.
    >> Share

  527. YU N, Sriranganathan D, Walker GJ, Sazonovs A, et al
    Prevalence of NUDT15 genetic variants and incidence of thiopurine-induced leukopenia in Inflammatory Bowel Disease: A systematic review and meta-analysis.
    J Crohns Colitis. 2023 Jun 22:jjad107. doi: 10.1093.
    >> Share

  528. BURISCH J, Safroneeva E, Laoun R, Ma C, et al
    Lack of benefit for early escalation to advanced therapies in ulcerative colitis: critical appraisal of current evidence.
    J Crohns Colitis. 2023 Jun 22:jjad106. doi: 10.1093.
    >> Share

  529. KOPCZYNSKA M, Crooks B, Deutsch L, Conley T, et al
    Disease recurrence and long-term outcomes following the development of intestinal failure in Crohn's disease: over 20 years of experience from a national reference centre.
    J Crohns Colitis. 2023 Jun 21:jjad105. doi: 10.1093.
    >> Share

  530. FOCHT G, Kuint RC, Greer MC, Pratt LT, et al
    Prospective Validation of the Lemann Index in Children: A Report From the Multicentre Image Kids Study.
    J Crohns Colitis. 2023;17:943-949.
    >> Share

  531. KANTASIRIPITAK W, Wicha SG, Thomas D, Hoffman I, et al
    A Model-Based Tool for Guiding Infliximab Induction Dosing to Maximize Long-term Deep Remission in Children with Inflammatory Bowel Diseases.
    J Crohns Colitis. 2023;17:896-908.
    >> Share

  532. GISBERT JP, Chaparro M
    Vaccines in Children Exposed to Biological Agents In Utero and/or During Breastfeeding: Are They Effective and Safe?
    J Crohns Colitis. 2023;17:995-1009.
    >> Share

  533. WEBER MC, Bauer J, Buck A, Clees Z, et al
    Perioperative Low-Dose Prednisolone Treatment Has Beneficial Effects on Postoperative Recovery and Anastomotic Healing in a Murine Colitis Model.
    J Crohns Colitis. 2023;17:950-959.
    >> Share

  534. SOLITANO V, Vuyyuru SK, MacDonald JK, Zayadi A, et al
    Efficacy and safety of advanced oral small molecules for inflammatory bowel disease: Systematic review and meta-analysis.
    J Crohns Colitis. 2023 Jun 15:jjad100. doi: 10.1093.
    >> Share

  535. JANSEN FM, van Linschoten RCA, Kievit W, Smits LJT, et al
    Cost-effectiveness analysis of increased adalimumab dose intervals in Crohn's disease patients in stable remission: the randomised controlled LADI trial.
    J Crohns Colitis. 2023 Jun 13:jjad101. doi: 10.1093.
    >> Share

  536. MATINI L, Chapman TP, Kantschuster R, Wilson J, et al
    Development of the Escalation of Therapy or Intervention (ETI) calculator for patients with ulcerative colitis using ePROMS.
    J Crohns Colitis. 2023 Jun 12:jjad099. doi: 10.1093.
    >> Share

  537. EDER P, Verstock B, Culver E, Dragoni G, et al
    Autoimmune pancreatitis in patients with inflammatory bowel disease - a real-world multicentre collaborative ECCO CONFER study.
    J Crohns Colitis. 2023 Jun 7:jjad097. doi: 10.1093.
    >> Share

  538. SUN Z, Braga-Neto MB, Xiong Y, Bhagwate AV, et al
    Hypomethylation and overexpression of Th17-associated genes is a hallmark of intestinal CD4+ lymphocytes in Crohn's disease.
    J Crohns Colitis. 2023 Jun 6:jjad093. doi: 10.1093.
    >> Share

  539. SABINO J, Tarassishin L, Eisele C, Hawkins K, et al
    Influence of Early Life Factors, including Breastmilk Composition, on the Microbiome of Infants Born to Mothers with and without Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Jun 6:jjad096. doi: 10.1093.
    >> Share

  540. HOLTEN KA, Bernklev T, Opheim R, Johansen I, et al
    Fatigue in patients with newly diagnosed inflammatory bowel disease: Results from a prospective inception cohort, the IBSEN III study.
    J Crohns Colitis. 2023 Jun 5:jjad094. doi: 10.1093.
    >> Share

    May 2023
  541. BRUGGELING CE, Te Groen M, Garza DR, van Heeckeren Tot Overlaer F, et al
    Bacterial oncotraits rather than spatial organization are associated with dysplasia in ulcerative colitis.
    J Crohns Colitis. 2023 May 27:jjad092. doi: 10.1093.
    >> Share

  542. MOTWANI KK, Hashash JG, Farraye FA, Kappelman MD, et al
    Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
    J Crohns Colitis. 2023 May 26:jjad085. doi: 10.1093.
    >> Share


  543. Correction to: Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study.
    J Crohns Colitis. 2023 May 24:jjad082. doi: 10.1093.
    >> Share

  544. PEYRIN-BIROULET L, Arenson E, Rubin DT, Siegel CA, et al
    A comparative evaluation of the measurement properties of three histological indices of mucosal healing in ulcerative colitis: Geboes Score, Robarts Histopathology Index, and Nancy Index.
    J Crohns Colitis. 2023 May 24:jjad087. doi: 10.1093.
    >> Share

  545. HONAP S, Buisson A, Danese S, Laurent B, et al
    Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 May 23:jjad090. doi: 10.1093.
    >> Share

  546. PIERRE N, Vieujean S, Peyrin-Biroulet L, Meuwis MA, et al
    Defining biological remission in Crohn's disease: interest, challenges and future directions.
    J Crohns Colitis. 2023 May 19:jjad086. doi: 10.1093.
    >> Share

  547. STAFFORD IS, Ashton JJ, Mossotto E, Cheng G, et al
    Supervised machine learning classifies inflammatory bowel disease patients by subtype using whole exome sequencing data.
    J Crohns Colitis. 2023 May 19:jjad084. doi: 10.1093.
    >> Share

  548. KABIR M, Thomas-Gibson S, Tozer PJ, Warusavitarne J, et al
    DECIDE: Delphi Expert Consensus Statement on Inflammatory Bowel Disease Dysplasia Shared Management Decision-Making.
    J Crohns Colitis. 2023 May 12:jjad083. doi: 10.1093.
    >> Share

  549. ITZKOWITZ S, Farraye FA, Limburg P, Gagrat Z, et al
    Assessment of Stool DNA Markers to Detect Colorectal Neoplasia in Patients with Inflammatory Bowel Disease: A Multi-site Case-control Study.
    J Crohns Colitis. 2023 May 11:jjad069. doi: 10.1093.
    >> Share

  550. OHLMANN H, Lanters LR, Theysohn N, Langhorst J, et al
    Distinct alterations in central pain processing of visceral and somatic pain in quiescent ulcerative colitis compared to irritable bowel syndrome and health.
    J Crohns Colitis. 2023 May 10:jjad080. doi: 10.1093.
    >> Share

  551. IRVING PM
    Thiopurines for Ulcerative Colitis: Old Favourite or Old Hat?
    J Crohns Colitis. 2023 May 4:jjad062. doi: 10.1093.
    >> Share

  552. BAI L, Dermadi D, Kalesinskas L, Dvorak M, et al
    Mass-Cytometry-Based Quantification of Global Histone Post-Translational Modifications at Single-Cell Resolution Across Peripheral Immune Cells in IBD.
    J Crohns Colitis. 2023;17:804-815.
    >> Share

  553. GODNY L, Svolos V, Williams AJ, Czuber-Dochan W, et al
    Multidisciplinary Perinatal Care in IBD.
    J Crohns Colitis. 2023;17:663-680.
    >> Share

  554. VERMEIRE S, Solitano V, Peyrin-Biroulet L, Tilg H, et al
    Obefazimod: A First-in-class Drug for the Treatment of Ulcerative Colitis.
    J Crohns Colitis. 2023 May 2:jjad067. doi: 10.1093.
    >> Share

    April 2023
  555. MCCURDY JD, Weng R, Parlow S, Dawkins YM, et al
    Video capsule endoscopy can identify occult luminal Crohn's disease in patients with isolated perianal fistulas.
    J Crohns Colitis. 2023 Apr 26:jjad078. doi: 10.1093.
    >> Share

  556. ATIA O, Friss C, Ledderman N, Greenfeld S, et al
    Thiopurines have longer treatment durability than methotrexate in adults and children with Crohn's Disease: a nationwide analysis from the epi-IIRN cohort.
    J Crohns Colitis. 2023 Apr 26:jjad076. doi: 10.1093.
    >> Share

  557. KURIAKOSE KUZHIYANJAL AJ, Nigam GB, Antoniou GA, Farraye FA, et al
    Management of Inflammatory Bowel Disease Using E-Health Technologies: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023 Apr 26:jjad075. doi: 10.1093.
    >> Share

  558. TSCHURTSCHENTHALER M, Verstockt B
    Targeting a Hallmark of Crohn's Disease: Browning of the Hypertrophic Mesenteric Adipose Tissue as a Novel Strategy to Reduce Inflammation?
    J Crohns Colitis. 2023 Apr 26:jjad059. doi: 10.1093.
    >> Share

  559. ALSOUD D, Ho J, Verstockt B
    The Serum-Based Endoscopic Healing Index Can Monitor Therapeutic Response in Crohn's Disease.
    J Crohns Colitis. 2023 Apr 26:jjad077. doi: 10.1093.
    >> Share

  560. HASKEY N, Estaki M, Ye J, Shim RK, et al
    A Mediterranean Diet Pattern improves intestinal inflammation concomitant with reshaping of the bacteriome in ulcerative colitis: A randomized controlled trial.
    J Crohns Colitis. 2023 Apr 24:jjad073. doi: 10.1093.
    >> Share

  561. LAURI G, D'Amico F, Allocca M, Palumbo D, et al
    Ustekinumab as induction and maintenance therapy in patients with inflammatory bowel disease and type II autoimmune pancreatitis: report of two cases.
    J Crohns Colitis. 2023 Apr 22:jjad072. doi: 10.1093.
    >> Share

  562. ALLOCCA M, Dell'Avalle C, Furfaro F, Zilli A, et al
    Early intestinal ultrasound predicts long-term endoscopic response to biologics in ulcerative colitis.
    J Crohns Colitis. 2023 Apr 21:jjad071. doi: 10.1093.
    >> Share

  563. GORELIK Y, Ghersin I, Shlon D, Friss C, et al
    Association of Antibiotic Use with Durability of Biologic Agents in Inflammatory Bowel Disease: a report from the epi-IIRN.
    J Crohns Colitis. 2023 Apr 21:jjad070. doi: 10.1093.
    >> Share

  564. LIGHTNER AL, Reese J, Ream J, Nachand D, et al
    A Phase IB/IIA Study of Allogeneic, Bone Marrow-derived, Mesenchymal Stem Cells for the Treatment of Refractory Ileal-anal Anastomosis and Peripouch Fistulas in the Setting of Crohn's Disease of the Pouch.
    J Crohns Colitis. 2023;17:480-488.
    >> Share

  565. CAO D, Qian K, Zhao Y, Hong J, et al
    Association of Neutrophil Extracellular Traps with Fistula Healing in Patients with Complex Perianal Fistulizing Crohn's Disease.
    J Crohns Colitis. 2023;17:580-592.
    >> Share

  566. VIEUJEAN S, De Vos M, Paridaens K, Daftary GS, et al
    Fertility and Assisted Reproductive Technologies Outcomes of Women with Non-surgically Managed Inflammatory Bowel Diseases: A Systematic Review.
    J Crohns Colitis. 2023;17:614-632.
    >> Share

  567. NIGHOT M, Liao PL, Morris N, McCarthy D, et al
    Long-Term Use of Proton Pump Inhibitors Disrupts Intestinal Tight Junction Barrier and Exaggerates Experimental Colitis.
    J Crohns Colitis. 2023;17:565-579.
    >> Share

  568. CHEN J, Wellens J, Kalla R, Fu T, et al
    Intake of Ultra-processed Foods Is Associated with an Increased Risk of Crohn's Disease: A Cross-sectional and Prospective Analysis of 187 154 Participants in the UK Biobank.
    J Crohns Colitis. 2023;17:535-552.
    >> Share

  569. CHUGH R, Braga-Neto MB, Fredrick TW, Ramos GP, et al
    Multicentre Real-world Experience of Upadacitinib in the Treatment of Crohn's Disease.
    J Crohns Colitis. 2023;17:504-512.
    >> Share

  570. SHARMA T, Ma C, Sedano R, Hanzel J, et al
    Placebo Response Rates in Randomized Controlled Trials for Perianal Crohn's Disease: A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2023;17:644-658.
    >> Share

  571. ELMAGHRAWY K, Fleming P, Fitzgerald K, Cooper S, et al
    The Oral Microbiome in Treatment-Naive Paediatric IBD Patients Exhibits Dysbiosis Related to Disease Severity that Resolves Following Therapy.
    J Crohns Colitis. 2023;17:553-564.
    >> Share

  572. ZHAO J, Lin Z, Ying P, Zhao Z, et al
    circSMAD4 Promotes Experimental Colitis and Impairs Intestinal Barrier Functions by Targeting Janus Kinase 2 Through Sponging miR-135a-5p.
    J Crohns Colitis. 2023;17:593-613.
    >> Share

  573. DRAGONI G, Allocca M, Myrelid P, Noor NM, et al
    Results of the Eighth Scientific Workshop of ECCO: Diagnosing postoperative recurrence of Crohn's disease after an ileocolonic resection with ileocolonic anastomosis.
    J Crohns Colitis. 2023 Apr 18:jjad055. doi: 10.1093.
    >> Share

  574. RIVIERE P, Bislenghi G, Hammoudi N, Verstockt B, et al
    Results of the Eighth Scientific Workshop of ECCO: Pathophysiology and risk factors of postoperative Crohn's disease recurrence after an ileocolic resection.
    J Crohns Colitis. 2023 Apr 18:jjad054. doi: 10.1093.
    >> Share

  575. FERRANTE M, Pouillon L, Manosa M, Savarino E, et al
    Results of the Eighth Scientific Workshop of ECCO: Prevention and treatment of postoperative recurrence in patients with Crohn's disease undergoing an ileocolonic resection with ileocolonic anastomosis.
    J Crohns Colitis. 2023 Apr 18:jjad053. doi: 10.1093.
    >> Share

  576. YAZAKI T, Kawashima K, Ishihara S
    Azathioprine-induced porto-sinusoidal vascular disease complicated with esophageal varices in Crohn's disease patient - Case report.
    J Crohns Colitis. 2023 Apr 17:jjad066. doi: 10.1093.
    >> Share


  577. Erratum to: Anogenital Crohn's Disease and Granulomatosis: A Systematic Review of Epidemiology, Clinical Manifestations, and Treatment.
    J Crohns Colitis. 2023 Apr 15:jjad044. doi: 10.1093.
    >> Share

  578. MAGRO F, Pai RK, Kobayashi T, Jairath V, et al
    Resolving Histologic Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programs.
    J Crohns Colitis. 2023 Apr 14:jjad050. doi: 10.1093.
    >> Share

  579. JANSEN D, Falony G, Vieira-Silva S, Simsek C, et al
    Community Types Of The Human Gut Virome Are Associated With Endoscopic Outcome In Ulcerative Colitis.
    J Crohns Colitis. 2023 Apr 13:jjad061. doi: 10.1093.
    >> Share

  580. DRAGONI G, Gottin M, Innocenti T, Lynch EN, et al
    "Correlation of ultrasound scores with endoscopic activity in Crohn's disease: a prospective exploratory study".
    J Crohns Colitis. 2023 Apr 6:jjad068. doi: 10.1093.
    >> Share

  581. DOHERTY J, O Morain N, Stack R, Tosetto M, et al
    Reduced serological response to COVID-19 booster vaccine is associated with reduced B cell memory in patients with Inflammatory Bowel Disease; VARIATION (VAriability in Response in IBD AgainsT SARS-COV-2 ImmunisatiON).
    J Crohns Colitis. 2023 Apr 5:jjad065. doi: 10.1093.
    >> Share

  582. FURUKAWA S, Mizushima T, Nakaya R, Shibata M, et al
    Darvadstrocel for Complex Perianal Fistulas in Japanese Adults with Crohn's Disease: A Phase 3 Study.
    J Crohns Colitis. 2023;17:369-378.
    >> Share

  583. JOHANSEN MP, Wewer MD, Nordholm-Carstensen A, Burisch J, et al
    Perianal Crohn's Disease and the Development of Colorectal and Anal Cancer: A Systematic Review and Meta-analysis.
    J Crohns Colitis. 2023;17:361-368.
    >> Share

  584. JOUSTRA V, van Sabben J, van der Does de Willebois E, Duijvestein M, et al
    Benefit of Risk-stratified Prophylactic Treatment on Clinical Outcome in Postoperative Crohn's Disease.
    J Crohns Colitis. 2023;17:318-328.
    >> Share

  585. WONG ECL, Moayyedi P, Narula N
    Beyond the White Pill: Advocating for Racial Diversity in IBD Trials.
    J Crohns Colitis. 2023;17:459-461.
    >> Share

  586. ASHTON JJ, Seaby EG, Beattie RM, Ennis S, et al
    NOD2 in Crohn's Disease-Unfinished Business.
    J Crohns Colitis. 2023;17:450-458.
    >> Share

    March 2023
  587. AXELRAD J, Olen O, Soderling J, Roelstraete B, et al
    Inflammatory Bowel Disease and Risk of Colorectal Polyps: A nationwide population-based cohort study from Sweden.
    J Crohns Colitis. 2023 Mar 30:jjad056. doi: 10.1093.
    >> Share

  588. CHEN LA, Oliva-Hemker M, Radin A, Weidner M, et al
    Longitudinal bile acid composition changes following fecal microbiota transplantation for Clostridioides difficile infection in children with and without underlying inflammatory bowel disease.
    J Crohns Colitis. 2023 Mar 29:jjad057. doi: 10.1093.
    >> Share

  589. JANKER L, Schuster D, Bortel P, Hagn G, et al
    Multi-omics empowered deep phenotyping of ulcerative colitis identifies biomarker signatures reporting functional remission states.
    J Crohns Colitis. 2023 Mar 24:jjad052. doi: 10.1093.
    >> Share

  590. FADEL MG, Geropoulos G, Warren OJ, Mills SC, et al
    Risks factors associated with the development of Crohn's disease after ileal pouch-anal anastomosis for ulcerative colitis: a systematic review and meta-analysis.
    J Crohns Colitis. 2023 Mar 24:jjad051. doi: 10.1093.
    >> Share

  591. DE CODES LMG, de Jesus ACC, de Codes JJG, Ferreira RF, et al
    Anorectal function and clinical characteristics associated with fecal incontinence in patients with Crohn's disease.
    J Crohns Colitis. 2023 Mar 23:jjad048. doi: 10.1093.
    >> Share

  592. ALLEZ M, Sands BE, Feagan BG, D'Haens G, et al
    A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel-arm, Multicenter Study Evaluating the Safety and Efficacy of Tesnatilimab in Patients With Moderately to Severely Active Crohn's Disease.
    J Crohns Colitis. 2023 Mar 20:jjad047. doi: 10.1093.
    >> Share

  593. RUNDE J, Veseli I, Fogarty EC, Watson AR, et al
    Transient Suppression of Bacterial Populations Associated with Gut Health is Critical in Success of Exclusive Enteral Nutrition for Children with Crohn's Disease.
    J Crohns Colitis. 2023 Mar 19:jjad031. doi: 10.1093.
    >> Share

  594. JONGSMA MME, Costes LMM, Tindemans I, Cozijnsen MA, et al
    Serum immune profiling in pediatric Crohn's disease demonstrates stronger immune modulation with first-line infliximab than conventional therapy and pre-treatment profiles predict clinical response to both treatments.
    J Crohns Colitis. 2023 Mar 19:jjad049. doi: 10.1093.
    >> Share

  595. ZUO L, Geng Z, Song X, Li J, et al
    Browning of mesenteric white adipose tissue in Crohn's disease: a new pathological change and therapeutic target.
    J Crohns Colitis. 2023 Mar 18:jjad046. doi: 10.1093.
    >> Share

  596. ROSS ADB, Zilbauer M
    Validation of IBD-associated Whole-blood DNA Methylation Changes-Where Do We Go From Here?
    J Crohns Colitis. 2023;17:151-152.
    >> Share

  597. HARVEY PR, Trudgill NJ
    Venous Thromboembolism Following Discharge from Hospital in Patients Admitted for Inflammatory Bowel Diseases-Authors' Reply.
    J Crohns Colitis. 2023;17:306.
    >> Share

  598. RIVIERE P, Pekow J, Hammoudi N, Wils P, et al
    Comparison of the Risk of Crohn's Disease Postoperative Recurrence Between Modified Rutgeerts Score i2a and i2b Categories: An Individual Patient Data Meta-analysis.
    J Crohns Colitis. 2023;17:269-276.
    >> Share

  599. ARKENBOSCH JHC, Beelen EMJ, Dijkstra G, Romberg-Camps M, et al
    Prophylactic Medication for the Prevention of Endoscopic Recurrence in Crohn's Disease: a Prospective Study Based on Clinical Risk Stratification.
    J Crohns Colitis. 2023;17:221-230.
    >> Share

  600. GONCZI L, Lakatos L, Kurti Z, Golovics PA, et al
    Incidence, Prevalence, Disease Course, and Treatment Strategy of Crohn's Disease Patients from the Veszprem Cohort, Western Hungary: A Population-based Inception Cohort Study Between 2007 and 2018.
    J Crohns Colitis. 2023;17:240-248.
    >> Share

  601. SEBASTIAN S, Segal JP, Hedin C, Pellino G, et al
    ECCO Topical Review: Roadmap to Optimal Peri-Operative Care in IBD.
    J Crohns Colitis. 2023;17:153-169.
    >> Share

  602. DAI C, Huang YH
    Venous Thromboembolism Following Discharge from Hospital Among Patients Admitted for Inflammatory Bowel Diseases.
    J Crohns Colitis. 2023;17:305.
    >> Share

  603. LIANG ZX, Liu HS, Xiong L, Zeng ZW, et al
    GAS6 From CD200+ Adipose-Derived Stem Cells Mitigates Colonic Inflammation in a Macrophage-Dependent Manner.
    J Crohns Colitis. 2023;17:289-301.
    >> Share

  604. ALBUQUERQUE A, Cappello C, Stirrup O, Selinger CP, et al
    Anal high-risk human papillomavirus infection, squamous intraepithelial lesions and anal cancer in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    J Crohns Colitis. 2023 Mar 17:jjad045. doi: 10.1093.
    >> Share

  605. DOTAN I, Feagan BG, Taliadouros V, Oortwijn A, et al
    Efficacy of Filgotinib in Patients with Ulcerative Colitis by Line of Therapy in the Phase 2b/3 SELECTION Trial.
    J Crohns Colitis. 2023 Mar 16:jjad039. doi: 10.1093.
    >> Share

  606. JIMBO K, Hosoi K, Suzuki M, Kyodo R, et al
    Accuracy of Transperineal Ultrasonography for Assessing Rectal Lesions in Pediatric Ulcerative Colitis: A Prospective Study.
    J Crohns Colitis. 2023 Mar 15:jjad035. doi: 10.1093.
    >> Share

  607. MACALUSO FS, Ventimiglia M, Orlando A
    Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies.
    J Crohns Colitis. 2023 Mar 13:jjad043. doi: 10.1093.
    >> Share

  608. JANSSEN LM, Creemers RH, van Bodegraven AA, Pierik MJ, et al
    A systematic review on long-term efficacy outcome measures in Crohn's disease patients.
    J Crohns Colitis. 2023 Mar 13:jjad037. doi: 10.1093.
    >> Share


  609. Erratum to: Post-inflammatory Polyp Burden as a Prognostic Marker of Disease-outcome in Patients with Inflammatory Bowel Disease.
    J Crohns Colitis. 2023 Mar 9:jjad028. doi: 10.1093.
    >> Share

  610. YAMAMOTO T, Nakase H, Watanabe K, Shinzaki S, et al
    Diagnosis and Clinical Features of Perianal Lesions in Newly Diagnosed Crohn's Disease: Subgroup Analysis from Inception Cohort Registry Study of Patients with Crohn's Disease (iCREST-CD).
    J Crohns Colitis. 2023 Mar 4:jjad038. doi: 10.1093.
    >> Share

  611. STEENHOLDT C, Ovesen PD, Brynskov J, Seidelin JB, et al
    Tofacitinib for acute severe ulcerative colitis: a systematic review.
    J Crohns Colitis. 2023 Mar 1:jjad036. doi: 10.1093.
    >> Share

    February 2023
  612. LOWENBERG M, Volkers A, van Gennep S, Mookhoek A, et al
    Mercaptopurine for the treatment of ulcerative colitis - a randomised placebo-controlled trial.
    J Crohns Colitis. 2023 Feb 27:jjad022. doi: 10.1093.
    >> Share

  613. LAHARIE D, Mary JY
    Should we target complete endoscopic healing in patients with acute severe ulcerative colitis?
    J Crohns Colitis. 2023 Feb 25:jjad032. doi: 10.1093.
    >> Share

    December 2022
  614. LEE C, Song JH, Cha YE, Chang DK, et al
    Intestinal Epithelial Responses to IL-17 in Adult Stem Cell-derived Human Intestinal Organoids.
    J Crohns Colitis. 2022;16:1911-1923.
    >> Share

  615. PELLINO G, Rottoli M, Mineccia M, Frontali A, et al
    Segmental Versus Total Colectomy for Crohn's Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study.
    J Crohns Colitis. 2022;16:1853-1861.
    >> Share

  616. ARP L, Jansson S, Wewer V, Burisch J, et al
    Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases - A Systematic Review and Meta-Analysis.
    J Crohns Colitis. 2022;16:1933-1945.
    >> Share

  617. BARBERIO B, Savarino E, Verstockt B, Fumery M, et al
    Hereditary Colorectal Cancer Syndromes and Inflammatory Bowel Diseases: an ECCO CONFER Multicentre Case Series.
    J Crohns Colitis. 2022;16:1845-1852.
    >> Share

  618. BATTAT R
    Serum Monitoring of Recurrence in Post-Operative Crohn's Disease: Have We Arrived?
    J Crohns Colitis. 2022;16:1795-1796.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016